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Cardiac valve disease is a major health burden affecting around 5% of the population. 
Two of the most common cardiac valve disease include mitral valve prolapse (MVP) and 
bicuspid aortic valve disease (BAV). Currently treatment options consist of invasive 
surgeries to either repair or replace the damages valve tissues. Evidence suggests that 
both MVP and BAV are congenital diseases that present complications in patients later in 
life. Treatment options for these diseases are lacking due to an incomplete understanding 
of the molecular causes.  
 Mitral valve prolapse (MVP) is one of the most common forms of cardiac valve 
disease and affects ~2-3% of the human population. MVP can lead to secondary 
complications such as arrhythmias, heart failure, and sudden cardiac death and 1 in 10 
patients will require valve surgery. There are no effective nonsurgical treatments for 
MVP and therapeutic efforts have been hindered by an incomplete understanding of its 
fundamental causes. One accessible source of such information may come from genetic 
studies of MVP. We previously reported familial and GWAS studies that identified 
genetic mutations and/or excellent candidate targets as causal to MVP.  Pathway analyses 
suggested a common cellular and molecular thread between these studies and invoke the 
primary cilia as potential unifying mechanism. This discovery is further bolstered by our 
recent identification of a mutation in a cilia gene in a large family with MVP, DZIP1.  
Our data show genetic haploinsufficiency of primary cilia in cardiac valves leads to a 
non-syndromic mitral valve disease in mouse models whereas complete genetic ablation 
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enhances mitral valve phenotype severity and generation of bicuspid aortic valve (BAV).  
We present, for the first time, a potential common cellular and molecular thread through 
which MVP and potentially BAV can arise.  These studies define the primary cilia as a 
critical, and previously unrecognized facet of cardiac valve development.  Uncovering 
how valve disease genes regulate downstream signaling cascades will provide key 





























CHAPTER 1: INTRODUCTION 
 
In the United States it is estimated that 92.1 million adults have at least one type of 
cardiovascular disease, a number that is projected to grow to around 140 million US 
adults in 2030 (Benjamin, Blaha et al. 2017).  One of the most common cardiac diseases 
in today’s society is heart valve disease with a prevalence of about 5%, causing over 
24,000 deaths each year in the United States with no effective non-surgical treatment 
(Benjamin, Blaha et al. 2017).  Heart valve disease can either be acquired or congenital 
and shows variable expression and severity.  Thus, depending on the type of valve 
disease, heterogeneity and variability in age of clinical presentation is the rule versus the 
exception.  In addition to heart valve disease being a major cause of morbidity and 
mortality in the aged population, congenital or developmental defects in the 
cardiovascular system are the most common cause of infant deaths. How these defects 
occur, the mechanisms that result in the disease progression, and potential treatments 
options are poorly understood.  The overall goal of my research throughout the past 5 
years was to take genetic information from patients with common cardiac valve diseases 
and elucidate the reason that valve diseases occur.  Our studies have led to the uncovering 
of new molecular and cellular mechanisms during valve development. The following 
chapters will detail how we identified mechanisms underlying valve development and 
disease, the specific types of valve diseases we studied, and potential to harness this 






 The mammalian heart is composed of four chambers: 2 atria and 2 ventricles. 
Controlling unidirectional blood flow from the atria into the ventricles and out through 
the arterial connections are the cardiac valves (Fig 1.1). The atrioventricular mitral and 
tricuspid valves are positioned at the intersection between the left atrium/ventricle and the 
right atrium/ventricle, respectively. These sets of valves are critical for regulating proper 
blood flow that enters the heart and passes through the atria to the ventricles and are thus 
called “in-flow” valves.  During ventricular contraction, these valves shut and blood exits 
through outlet segments.  Blood from the left ventricle exits through the aortic valves, 
into the aorta and serves to feed the body.  The deoxygenated blood subsequently returns 
to the right side of the heart and, upon right ventricular contraction, is pumped out 
through the pulmonic valves and into the pulmonary arteries on its way to the lungs (Fig 
1.1).  Oxygenated blood returns to the left side of the heart, and the cycle continues for 
the duration of life.  Defects in the function of any of these valves results in changes in 
the proper cycling of blood and can lead to serious health complications and death.  Thus, 
understanding how valve defects occur is critical for improving patient health.  Defining 
how valves form during development will likely provide key insight into how their 
dysfunction occurs, with the hypothesis that altered construction of these tissues will 








Figure 1.1 The Human Heart. Sketch showing the inside of a human heart. Oxygenated blood flows 
into the left atria from the lungs and travels through the mitral valve into the left ventricle. During 
contraction blood then moves through the aortic valves into the aorta and to the rest of the body. De-
oxygenated blood enters the heart through the superior vena cava into the right atrium through the 
tricuspid valve and into the right ventricle. De-oxygenated blood then leaves the heart traveling 






The Developmental Origin of Cardiac Valves: 
During development the heart valves form from rudimentary structures called 
“endocardial cushions”.  The outflow tract cushions develop into aortic and pulmonary 
valves (cusps) while the atrioventricular (inflow) cushions develop into mitral and 
tricuspid valves (leaflets). Orchestration of how these cushions form and mature into 
valve leaflets or cusps is complex and requires the integration of biomechanical stimuli, 
extracellular signals, intracellular signaling cascades and transcriptional regulation of 
target genes, all occurring in the heart which is continually beating. Alterations in any 
steps of the developmental process are known to cause defects in valve formation. Based 
on these previous studies, many valve diseases are known to have a developmental origin 
and underscore the importance of defining how the integration of molecular, mechanical 
and biochemical cues provide a road-map for valve development. 
The structure and function of the valves are dependent on how they are built 
during development. Cardiac valve development occurs in multiple stages; formation of 
the cardiac jelly, migration of endocardial cells into the cardiac jelly, proliferation and 
matrix deposition of post endothelial to mesenchymal transformation (EMT) cells, matrix 
compaction and elongation and stratification of valve matrix into distinct layers. Cardiac 
development begins with the migration of two populations of cells from the primitive 
streak, forming the primary and secondary heart fields. Around E8.0 in mouse, these two 
cell populations fuse to form the cardiac crescent (Combs and Yutzey 2009, Garside, 
Chang et al. 2013). The primary heart field cells give rise to the left ventricle, 
atrioventricular canal, and part of the right ventricle and atria while the second heart field 
contributes to the right ventricle, atria outflow tract, and interventricular septum. Around 
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E8.5, the cardiac crescent fuses, thereby generating a linear heart tube.  The heart tube 
consists of an outer myocardial layer and inner endocardial layer which are separated by 
a layer of extracellular matrix called the cardiac jelly composed mostly of proteoglycan 
glycosaminoglycans. This tube loops rightward to form the four-chambered mammalian 
heart. After looping to the right, the heart tube forms specified structures such as the 
atrioventricular (AV) junction and ventricular outflow tract (OFT). At this stage, 
myocardial cells begin secreting ECM. The initial stages of valvulogenesis begin with the 
formation of the atrioventricular (AV) and outflow tract cushions (OFT). The mural 
leaflets of the AV valve form through the formation of lateral cushions on the left and 
right side of the AV junction (Wessels, Markman et al. 1996). The superior and inferior 
endocardial cushions fuse together to form components of the AV septum which later 
fuses with the developing ventricular septum, mesenchymal cap and dorsal mesenchymal 
protrusion (DMP). Together these different structures form the valvuloseptal complex 
(Perez-Pomares, Phelps et al. 2002). This structure forms the anterior leaflet of the mitral 
valve and septal leaflet of the tricuspid valve. 
The cardiac cushions form when myocardium secretes ECM, called cardiac jelly, 
into the interstitial space between the endocardium and myocardium. This matrix is 
composed of collagens (I, III, IV), glycoproteins (fibronectin, laminin, fibrillin), and 
mucopolysaccharides (glycosaminoglycans like chondroitin sulfate and hyaluranate) 
(Manasek 1970).  As the cushion matures (E9.5-10.5), endocardial cells undergo 
endothelial to mesenchymal transformation (EMT) and migrate into the cardiac jelly 
(Markwald, Fitzharris et al. 1977). In order for cells to undergo this process, they must 
lose cell-cell junctions, cell polarity, transition into mesenchymal cells, and acquire a 
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migratory phenotype (Garside, Chang et al. 2013). Pioneering work by Markwald and 
Bernake in 1982 showed that a subset of endocardial cells from explanted AV canals, 
isolated prior to EMT were capable of transforming into mesenchymal cells with 
invasive, migratory potential (Bernanke and Markwald 1982). They, and others, also 
showed that this process is dependent on signals from the myocardium (Runyan and 
Markwald 1983, Mjaatvedt, Lepera et al. 1987).  
Two major players in this EMT process are TGFβ and BMP. These signals are 
important for embryonic development as deletion of either TGFβ or BMP result in 
embryonic lethality.  In early cushion formation, BMP is required for the activation of the 
endocardium, formation of the cardiac jelly, and for initiation and formation of the 
cushions.  BMP2 secreted by the myocardium is necessary for AV valve EMT while 
BMP4 is necessary for OFT cushion growth. Deletion of BMP2 specifically from the 
myocardium using Nkx2.5-Cre results in failure of cushion formation (Ma, Lu et al. 
2005). Mice lacking the BMP receptor ALK2 fail to transform into mesenchymal cells 
and result in embryonic lethality(Wang, Sridurongrit et al. 2005).   
TGFβ also plays a critical role in the EMT process through promotion of 
mesenchymal invasiveness (MacGrogan, Luxan et al. 2014, Bosada, Devasthali et al. 
2016).  TGFβ 1 and 2 are expressed during early cushion formation in the cardiac 
cushion mesenchyme and by the endocardium prior to invasion. TGFβ3 however is 
expressed after EMT and is not expressed in the endocardium suggesting its role may be 
in the later remodeling phase of valve development. Experiments show TGFβ is 
sufficient to induce EMT in chick explants. Treatment of explants with TGFβ1 induces 
EMT in the absence of the normally required AV myocardium (Potts and Runyan 1989, 
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Ramsdell and Markwald 1997). Additionally, neutralizing antibodies for TGFβ1 or 
TGFβ3 prevent the formation and migration of cushion mesenchymal cells.   
After receiving signals from the myocardium, endocardial cells then have to 
disconnect from each other in order to migrate into the cardiac jelly. Notch1 signaling 
during this time is important for cells undergoing EMT to delaminate from the 
endocardial layer. In Notch signaling mutants, cells fail to delaminate and migrate into 
the ECM. It is thought that Notch signaling induces expression of pro-migratory 
transcription factor Snail which directly represses VE-cadherin promoter activity (Combs 
and Yutzey 2009). Loss of endocardial cell-cell adhesion during EMT is associated with 
down regulation of VE-cadherin as well as neural cell adhesion molecule (N-CAM), 
vascular endothelial (VE)-cadherin, and platelet endothelial cell adhesion molecule 1 
(PECAM-1)(Crossin 1991, Baldwin, Shen et al. 1994).  
In addition to cells undergoing EMT a subpopulation of endothelial cells remain 
lining the cushion where they are necessary in forming a tight protective boarder. The 
endocardial transcription factor, nuclear factor of activated T cells-c1 (Nfatc1), is 
important in maintaining endothelial phenotype and promoting proliferation of 
endothelial cells which do not undergo the EMT process (Sugi, Yamamura et al. 2004, 
Wu, Wang et al. 2011, MacGrogan, Luxan et al. 2014, Bosada, Devasthali et al. 2016, 
Saxon, Baer et al. 2017).These endothelial cells do not undergo EMT and are maintained 
as the boundary of cushion development.   
After migrating into the cardiac jelly, EMT derived cells undergo a highly 
proliferative stage in order to populate the forming tissue. Fibroblast growth factor 
(FGFs) promote post-EMT mesenchymal cell proliferation. Treatment of chick 
	 20	
atrioventricular valve cushion (AVC) explants with FGF results in increased cell 
proliferation (Sugi, Ito et al. 2003). Epidermal growth factor (EGF), however, has the 
opposite effect. EGF inhibits BMP signaling which is necessary for activation of 
SMAD1/5/8.  Studies have shown mutations causing reduction in EGF signaling result in 
increased cell proliferation through activation of BMP (Person, Klewer et al. 2005).  
Mesenchymal cells during this stage in valve development express twist1, Msx1/2, Sox9 
and Tbx20, factors that have been shown to be important for promoting proliferation (de 
Vlaming, Sauls et al. 2012).  
Around E14.5 many cell processes are occurring including cell migration and 
ECM secretion and remodeling. Cells adopt a fibroblast-like phenotype where they 
produce fibrillar collagens and become contractile, breaking down and synthesizing 
matrix. These cells then express alpha smooth muscle actin (aSMA) a marker of activated 
fibroblasts. These processes are less well defined although some progress has recently 
been made.  During this stage in development, ECM compartments form and ultimately 
results in the beginning of zonal boundaries demarcated by areas of collagen and 
proteoglycan secretion. Additionally, between E14.5 and E18.5 cell density increases 
with condensation occurring first at the atrial side and expanding towards the ventricular 
side (Kruithof, Krawitz et al. 2007). Valvular interstitial cells increase expression of N-
cadherin, proliferating cell nuclear antigen (PCNA) and αSMA. N-cadherin promotes 
cell adhesion and is necessary for cell alignment and leaflet elongation. Improper 
alignment of cells within the leaflet results in disorganized matrix production and 
ultimately valve disease. At this stage cell polarity is important in order to begin properly 
aligning cells within the tissue.   
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Deposition and remodeling of matrix through compaction is also occurring at 
these later stages of valve development (E17.5-postnatal stages) as indicated by increase 
αSMA and BMP expression (Kruithof, Krawitz et al. 2007). BMP, periostin, and Nfatc1 
play important roles in this remodeling process. BMP is important in this stage of 
development as well because it regulates expression of Tbx2. Mice lacking BMP2 
expression fail to express Tbx2 which is necessary for increased ECM deposition (Combs 
and Yutzey 2009).  Periostin, a matricellular protein involved in connecting cell surface 
to structural ECM components, is also highly expressed. Studies have shown that 
periostin plays an important role in compaction of the cushion mesenchyme and is 
important for valve development (Ghatak, Misra et al. 2014). Loss of periostin results in 
a non-compacted myxomatous-like phenotype (Norris, Borg et al. 2008).  
Filamin-A (FLNA) is also very important for the remodeling stages of valve 
development. FLNA is a cytoskeletal actin-binding protein that when removed causes 
cardiac valvular dystrophy. Functionally, FLNA cross-links cortical actin filaments into 
three dimensional structures. Knockout mice have defects in post-EMT cardiac 
morphogenesis suggesting its role in valve remodeling. Other proteins expressed in the 
valve during this remodeling phase of development include the small GTPases Rho and 
Rac. These proteins function to interact with the actin cytoskeleton in order to compact 
the ECM.  
Mesenchymal cells stop expressing Twist1, Tbx20, Msx1, and Msx2 and begin to 
express markers of more differentiated lineages (Tao, Kotick et al. 2012). Interestingly, 
these markers often are similar to those found in cartilage and early bone formation 
(Combs and Yutzey 2009). Condensation of matrix in skeletal development is necessary 
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for patterning of condensed areas into bone. For this reason, expression of these markers 
in valve development might be required for ECM patterning into specified matrix 
regions. In the condensing late embryonic valves, BMP2 signals activate Sox9 
transcription factor and expression of aggrecan. In addition, FGF4 activates scleraxis and 
tenascin, genes that are characteristic of the collagen rich fibrosa layer of the valve.   
The valves continue to develop during late gestation and into postnatal times 
changing to accommodate different hemodynamic forces and molecular signals.  Cells in 
postnatal valve leaflets continue to remodel matrix and begin the elongation phase where 
proliferation within specified regions and apoptosis in other regions occurs. This is 
necessary in order to regulate valve growth to form a thin elongated valve. Molecular 
signals from FGF4 stimulates proliferation in the distal tip, while EGF and TGFβ 2 
prevent proliferation at the base of the developing valve (Sugi, Ito et al. 2003, Butcher 
and Markwald 2007). 
Finally, the valve undergoes ECM stratification and development of distinct 
spongiosa and fibrosa regions composed of mainly collagens and proteoglycans, 
respectively (Riem Vis, Kluin et al. 2011). Elastin expression is localized to the flow side 
of the valve while collagens are expressed in the fibrosa layer away from blood 
flow(Hinton and Yutzey 2011).  The developmental and molecular mechanisms 
regulating valve stratification are currently not known.  
 
Valve Cells Types 
The postnatal valve is composed of valvular interstitial cells (VIC), which 
constitute the majority of the valve and are typically fibroblastic, and valvular endothelial 
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cells (VEC) which cover the valve and provide a tight outer boarder. VICs are believed to 
have many different characteristics depending on their location within the tissue.  In fact, 
some people believe there are at least 5-10 different phenotypes of a valve interstitial cell 
(Liu, Joag et al. 2007, Horne, VandeKopple et al. 2015). These cells can range in 
phenotype from matrix remodeling activated fibroblast that express aSMA to dormant 
VICs that populate the leaflets.  VECs are critical for maintaining homeostasis in the 
valve through regulations of inflammation and vascular remodeling(Butcher and Nerem 
2007). Disruption of the endothelial boarder has been shown to lead to valve disease 
(Leask, Jain et al. 2003, Butcher and Markwald 2007, El-Hamamsy, Balachandran et al. 
2009). During disease, VECs have been shown to undergo EMT and repopulate the valve 
(Bischoff and Aikawa 2011).  
VICs are the cells that populate the valve and are responsible for matrix 
deposition and maintenance of the tri-layer ECM structure. They have great plasticity and 
can change back and forth between fibroblasts and smooth muscle cells secreting both 
matrix and matrix metalloproteases (MMPs). In healthy valves VICs are primarily 
quiescent however in disease they become activated and can become contractile and 
migratory(Rabkin-Aikawa, Farber et al. 2004).  VICs can respond to biochemical and 
biomechanical stresses.  For example, ex-vivo stretching can alter transcriptional 
responses and lead to increased expression of inflammatory genes. (Warnock, Nanduri et 
al. 2011). In addition, in experiments when valves are removed and placed under planar 
tension they up-regulate expression of α-smooth muscle actin. This leads to remodeling 
of ECM components through activation of RhoA (Gould, Yalcin et al. 2016).   
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Valve endothelial cells (VECs) also play an important role in valve biology. 
VECs are responsible for serving as a boundary between VICs and the hemodynamic 
environment of the heart. Since VECs are in contact with the circulation, they are 
exposed to shear stress and circulating signaling molecules, cytokines and other risk 
factors such as cholesterol, lipids and inflammatory cells (Huk, Austin et al. 2016). In this 
way VECs can also signal to underlying VICs to influence behavior and ECM 
production. Studies have shown that TGFb1 expressed by VECs can induce expression of 
Sox9 in developing VICs (Huk, Austin et al. 2016). In aortic valves, it has been shown 
that the VECs play a role in VIC response to stress, again demonstrating the importance 
of a proper endothelial border (Butcher and Nerem 2006).  
An additional cell type that is sometimes found in the valve are hematopoietic 
derived cells. This cell type is less well described and are thought to be derived from 
either infiltrating circulating cells or activation of osteoblastic phenotypes in resident 
VICs(Liu, Joag et al. 2007, Huk, Austin et al. 2016). In normal tissue and disease, 
circulating immune cells positive for CD45, infiltrate the valve tissue and have the ability 
to remodel matrix (Barth, Koster et al. 2005, Hajdu, Romeo et al. 2011). Our group has 
shown that in both humans and mice with myxomatous valve disease there is an increase 
in hematopoietic cell engraftment (Sauls, Toomer et al. 2015). Localization of these cells, 
in disease states, correlates with increased MMP2 expression suggesting that these cells 
are promoting myxomatous degeneration through a paracrine mechanism with resident 
VICs.   
 Although a large majority of the processes during valve development are the same 
among the different valves, there are some molecular and hemodynamic differences.  A 
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major difference between AV and OFT development is the contribution of different cell 
types and biomechanical forces. The consequences of these differences are not fully 
appreciated but are believed to contribute to the unique tissue-specific anatomical 
functions of each valve tissue.  
 
Outlet Valves 
The semilunar valves develop from two distinct cell populations, endocardial cells 
that undergo EMT and contribute to the proximal cushions, and neural crest cells (NCCs) 
that migrate to the distal cushions from the dorsal neural tube (Kelly, Brown et al. 2001). 
Early in development, NCCs from the aortic arch migrate to the developing cushion. At 
the same time, a subpopulation of cells undergo EMT and invade the cushions. Fusion of 
these two cell populations is essential for the formation of the aortic and pulmonic 
outlets. Shortly after the cushions are formed the intermediate part of the outflow tract 
splits into the aorta and the pulmonary trunk. This process is facilitated by migration of 
cells from the second heart field and fusion of two different populations of neural crest 
cells (Spicer, Bridgeman et al. 2014).     
 
Inlet Valves 
In addition to endocardially derived cells, the AV valves are also composed of 
epicardially derived cells (EPDCs). Epicardial cells expressing WT1  migrate into mainly 
the mural leaflets but also the septal leaflets beginning around E12 (Wessels, van den 
Hoff et al. 2012). As the valves continue to develop, between E12 and postnatal day 0, 
more of the leaflets are populated with EPDCs. In the mural leaflets, which are largely 
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derived from the lateral atrioventricular cushions, the EPDCs replace a significant 
amount of endocardially derived cells whereas the septal leaflets have very few EPDCs 
as a contributing cell population (Wessels, van den Hoff et al. 2012). This process is 
regulated, in part, by signaling of Bmp2 through its receptor Alk3. Loss of Alk3 in 
EPDCs results in loss of EPDC migration into the mural or posterior AV valve leading.  
Loss of this signaling pathway leads to enlarged valves during development and 
myxomatous valves in adult mice(Lockhart, Boukens et al. 2014).  
 
Biomechanical Influences 
Biomechanical forces are also a differing factor in the development of AV and 
OFT valves. It is well established that hemodynamics play a significant role in the 
development of the cardiac tissues. In the mature heart, blood flows from areas of low 
pressure regions such as the atria to those of high pressure regions in the ventricles. For 
this reason, the AV valves experience different pressures than the OFT valves. Studies 
have shown that the mechanical forces of the beating heart during development influence 
the formation and matrix composition of the valves (Butcher, McQuinn et al. 2007). 
Matrix within the valves is organized within specific regions based, at least partly, on the 
hemodynamic forces the valves are exposed to. In addition, the leaflet shape and 
constrains felt by the AV and OFT valves are different. In the mitral valve, the leaflets 
are connected to tendinous chords, which attach to the left ventricular myocardium via 
the papillary muscle. These fibrous structures provide tension to the mitral leaflets on a 
beat-by-beat basis and keep the tissues from billowing back into the left atrium.  The 
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outflow tract cusps, alternatively, do not have chordal structures and attach directly to the 
wall of the aorta.  
A study looking at postnatal valve remodeling showed that mitral valve leaflets 
and aortic cusps behaved differently in response to biomechanical forces. Mitral valve 
leaflets that underwent sustained increase in systolic load undergo significant lengthening 
compared to controls while there was no change in aortic valve annulus (Tibayan, Louey 
et al. 2015). The authors speculated that this change was caused by differences in the 
support systems of the different valves allowing the aortic valve to be resistant to load-
induced dilation. While dilation of the aortic annulus doesn’t change in response to 
biomechanical load, studies have shown that constriction of OFT during chick 
development results in decreased OFT cushion volume and altered gene expression in the 
cushions (Menon, Eberth et al. 2015, Menon, Eberth et al. 2017).  
 
Parallels Between Valve and Limb Development 
A parallel can be drawn between cardiac cushion development and limb bud 
development. Similar developmental processes occur in each tissue. Expression of 
cartilage, tendon, and bone are important for heart valve maturation and ECM 
remodeling. During disease development ECM boundaries are lost resulting in defects in 
mechanical function of the valve. Often, heart valve disease such as Marfans, Ehlers-
Danlos, and Stickler syndrome, occur because manifestation of connective tissue 
disorders that affect cartilage, tendon, bone and skin (Lincoln, Lange et al. 2006).   
Protein expression during limb and valve development are also very similar. 
Sox9, BMP2, and aggrecan, for example, are all important for differentiation and 
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remodeling in both tissues.  In the developing limb bud BMP induces expression of Sox9 
and aggrecan which are necessary for differentiation of chondrocytes into bone 
(Akiyama, Chaboissier et al. 2002). This pathway is also expressed during valve 
development. BMP2 is highly expressed by the developing cushion tissue where it also 
induces Sox9 and aggrecan expression (Lincoln, Kist et al. 2007). Sox9 during late 
embryonic valve development is necessary for proper valve remodeling.  
Signaling mechanisms between the two tissues seems to also be conserved. In the 
limb bud, distinct zonal boundaries are defined by secreted signals in those locations, one 
of which is hedgehog signaling. In the valve, these regions coincide with differential gene 
expression of proteins such as collagens and proteoglycans. Currently the molecular cues 
that cause zonal boundaries and cellular phenotypic changes during valvulogenesis are 
unclear. However, one can postulate that similar to the limb bud, these signals most likely 
will consist of gradient of morphogens and differences in receptor expression (Coutinho 
and Antunes 2017). 
Strong evidence has been provided showing a developmental basis for many 
valve diseases (Garg, Muth et al. 2005, Hinton and Yutzey 2011, Durst, Sauls et al. 
2015). Therefore, it is important to recognize that mutations that occur at conception 
might be asymptomatic at birth and through childhood but may result in disease 
phenotypes later in life. Mitral valve prolapse for example has been described in the past 
as a disease of aging, however recent studies from our lab and others have shown that 
MVP is in fact a congenital heart disease with defects in valve development resulting in 
impaired adult valves (Durst, Sauls et al. 2015). This idea, that developmental changes 
can cause disease later in a patient’s life appears to be a reoccurring theme, as our lab and 
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others have noticed (Hinton, Alfieri et al. 2008, Markwald, Norris et al. 2010, Norris, 
Moreno-Rodriguez et al. 2010, Lockhart, Boukens et al. 2014, Durst, Sauls et al. 2015, 
Prakash, Borreguero et al. 2017).  Another well studied congenitally based cardiovascular 
valve disease is bicuspid aortic valve (BAV). Patients with BAV also have 
developmentally based valve disease that progresses overtime into a myxomatous 
phenotype. The mechanism by which these diseases occur and progress is poorly 
understood and currently the only treatment option is surgery for valve repair or 
replacement. Therefore, understanding these developmental processes is essential for 
determining disease mechanisms and ultimately therapeutic targets. 
 
Bicuspid Aortic Valve Disease 
Bicuspid aortic valve (BAV) disease is one of the most common congenital valvular heart 
defects affecting between 0.5-1.2% of the population(Martin, Kloesel et al. 2015, Martin, 
Lorca et al. 2017). BAV is just one of many left-sided heart defects such as aortic 
stenosis, coarctation of the aorta, mitral valve abnormalities and hypoplastic left heart 
(Martin, Kloesel et al. 2015). BAV is a congenital heart defect that results in defects in 
the formation of the three aortic cusps, either by failure of one of the cusps to form or 
fusion of two cusps. Often, BAV occurs with other aortic valve diseases such as 
aneurism, infective endocarditis, calcific aortic valve, and thrombus formation 
(Abdulkareem, Smelt et al. 2013). Patients with BAV have a higher occurrence of aortic 
valve replacement and at a younger age than population norms (Joziasse, Vink et al. 
2011). Clinically, BAV is usually non-syndromic but can be diagnosed in patients that 
have other confounding diseases such as Marfan syndrome, Holt-Oram syndrome, 
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ventricular noncompaction, adult-onset aortopathy, and Loeys-Dietz syndrome(Martin, 
Kloesel et al. 2015). The etiology of non-syndromic BAV is still unclear, although 
evidence suggests some form of genetic inheritance. Familial studies suggest an 
autosomal dominant method for inheritance, with implications for Notch1 and GATA5 as 
causal (Huntington, Hunter et al. 1997, Bonachea, Chang et al. 2014).  
BAV is diagnosed primarily by transthoracic echocardiography but sometimes is 
confirmed by transesophageal and 3-dimensional echocardiography. Functionally, BAV 
causes aortic regurgitation, aortic stenosis, infective endocarditis and dilatation of the 
thoracic ascending aorta. In addition, BAV patients often have an increased risk of aortic 
dissection and a high incidence of associated thoracic aortic aneurysm (TAA) formation. 
Around 50% of individuals with BAV also develop thoracic aortic aneurisms with 50% 
of those patients affected with aortic dissection and often death (Nadorlik, Bowman et al. 
2017).   
Patients with BAV often are associated with increased prevalence of aortic 
aneurysm (AA).  AA is described as an increase in aortic size above the normal threshold 
set for characteristics such as age, gender and body mass index. In general, the growth 
rate for AA is between 0.1 and 1.0 cm/year (Elefteriades 2010). The prevalence of 
ascending AA with BAV ranges from 35-80% depending on the study criteria; however, 
patients with AA have a substantial increase in morality risk once the aortic diameter 
reaches 6cm (Davies, Gallo et al. 2006).  
Multiple factors, such as genetic predisposition, epigenetic modifiers, age, 
diabetic status, and molecular regulation of MMP’s and TGFβ’s, are at play regarding the 
development of BAV and aneurysm. Genes such as ACTA2, MYH11, FLNA, and 
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SMAD3 have been identified as contributors for non-syndromic AA while FBN1, 
TGFBR1 and TGFBR2  have been implicated in the development of syndromic AA 
(Abdulkareem, Smelt et al. 2013). This information may be useful in discovering a 
mechanism for BAV as no genes have been found that prove to be conclusive for BAV 
with AA.   
One of the most common comorbidities associated with BAV is calcific aortic 
valve disease (CAVD). In fact, patient with BAV are more likely to develop CAVD with 
more than 50% of patients having severe aortic stenosis and requiring valve 
replacement(Peeters, Meex et al. 2017). CAVD develops when the mesenchymal cells of 
the aortic valve differentiate into bone precursors and start producing excess calcific 
ECM. During CAVD genes expressed during early valve development such as Sox9 are 
reactivated along with regulatory proteins that promote the development of cartilage and 
bone lineages(Wirrig and Yutzey 2014). CAVD occurs in two steps, first endothelial cells 
are activated or damaged leading to an immune response and second, fibrosis and 
increased calcification occurs. These changes then lead stiffening of the aorta and valves 
resulting in improper hemodynamic forces. CAVD is caused by complex interactions 
between multiple risk factors such as genetic mutations, environment, and 
biomechanics(Huk, Austin et al. 2016). Currently there is no treatment other than surgery 
because of the limited knowledge of underlying mechanisms.  
The mechanisms underlying CAVD is still poorly understood, however, evidence 
suggests that disease progression is driven by Notch, osteoprotegerin, Wnts and BMPs. 
Calcification has been seen in adult mice with mutations in Notch1 or RBPJ that have 
been fed a high fat diet (Garg, Muth et al. 2005, Nus, MacGrogan et al. 2011). In 
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addition, mice with endothelial deletion of the Notch1 ligand Jag1 have valve 
calcification later in life. It is believed that this process occurs through regulation of Hes 
and Hey, downstream transcription factors in the Notch pathway that regulate 
transcription of Runx2. In addition to Notch signaling, regulation of Sox9 may be 
important for development of calcific valves. Heterozygous loss of Sox9 using a Col2a1 
cre results in aortic valve calcification (Lincoln, Kist et al. 2007).   
In nearly all cases of severe BAV aortic dilation occur resulting in altered 
hemodynamic stresses and triggering increased MMP release. There are two theories for 
why the aortic dilatation occurs; either from hemodynamic stresses felt because of the 
bicuspid morphology or through disruption of developmental programs(Jain, Engleka et 
al. 2011, Longobardo, Jain et al. 2016). Often in BAV patients a wrinkling and folding of 
the cusp can occur causing an abnormality in the blood jet that is formed when compared 
to normal tricuspid aortic valves (Abdulkareem, Smelt et al. 2013). However, abnormal 
flow patterns cannot account for all BAV as hemodynamic forces do not correlate with 
aneurysm size seen in BAV patients (Martin, Kloesel et al. 2015).   
The genetic underpinnings of BAV are still unclear although familial studies have 
provided evidence for a potential autosomal-dominant pattern. Family recurrence rate for 
patients with BAV is approximately 35% (Huntington, Hunter et al. 1997).  Family 
members of patients with BAV often display BAV as well as other left-sided CHD. In 
seemingly sporadic cases of BAV, epidemiological studies have identified a 10% 
increased risk of BAV in siblings and offspring.  For this reason, the American Heart 
Association and American College of Cardiology recommends screening of first-degree 
relatives of affected adults (Nadorlik, Bowman et al. 2017). Preliminary evidence shows 
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that children who may be asymptomatic are at risk for increased ascending aortopathies 
(Nadorlik, Bowman et al. 2017). While there appears to be a genetic link for BAV strong 
genetic evidence has not been provided to account for a large majority of cases. Although 
not inclusive, mutations in Notch1 and GATA5 have been identity in some patients with 
BAV. In a large study, a family with aortic valve disease was screened for candidate 
genes. Linkage analysis was preformed to identify a single locus on chromosome 9. From 
this screen, NOTCH1 was identified and direct sequencing of NOTCH1 in affected 
patients identified a mutation in the gene(Garg, Muth et al. 2005).   
GATA5 has also been implicated in the development of BAV. Mice with 
endocardial cushion deletion of GATA5 results in right non-coronary BAV 
formation(Laforest, Andelfinger et al. 2011). GATA5 signals through both Tbx20 and 
Notch to regulate cell proliferation and migration of cells within the cushions. Loss of 
GATA5 results in decreased mesenchymal cells within the cushions. This however was 
not a very high penetrant phenotype with only 25% of knockout mice developing BAV.  
Human studies have also suggested a link between BAV and GATA5 
mutations(Padang, Bagnall et al. 2012, Bonachea, Chang et al. 2014). Four rare non-
synonymous variations within the GATA5 transcriptional activation domains were found 
from a large screen of 100 patients with BAV(Padang, Bagnall et al. 2012).  An 
additional screen for mutations in GATA5 was done on 78 patients with BAV(Bonachea, 
Chang et al. 2014). Sequencing data found two rare sequence variants in the GATA5 
gene with an estimated prevalence of 2.6%. These studies provide evidence for GATA5 
in the development of BAV however they are not explanatory in all cases. In addition to 
Notch1 and GATA5, links have been made between BAV and a variety of genes, Tgfβ, 
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KCNJ2, fibrillin, and nitric oxide synthase. More specifically, Tgfβ signaling has proved 
to be disrupted in patients with BAV and AA. During valve development, Tgfβ is 
important for EMT, cell migration and regulation of matrix deposition, processes that are 
often affected in patients with BAV. Mutations in Tgfβ have been found in humans with 
Loeys-Diets syndrome, a disease frequently diagnosed in patients with BAV(Loeys, Chen 
et al. 2005, Martin, Kloesel et al. 2015).  
Since BAV is a congenitally based disease, understanding the mechanisms that 
occur during development are important for understanding disease pathogenesis. 
Currently, little is understood about how a bicuspid instead of tricuspid valve forms. It is 
possible that this occurs from fusion of two leaflets or failure of one of the leaflets to 
form (De Mozzi, Longo et al. 2008). Normally the two leaflets that form are of unequal 
size with the larger leaflet having a central raphe or ridge that results from fusion of the 
commissures (Siu and Silversides 2010). The presence and position of the raphe varies 
among patients and diagnosis of a raphe or tricuspid valve can be contested between 
surgeon and pathologists (Joziasse, Vink et al. 2011). The fusion of the leaflets can occur 
in three ways, right-left, right-non-coronary, and left non-coronary(Nadorlik, Bowman et 
al. 2017). The most common fusion is of the right and left coronary cusps affecting about 
70% of BAVs. While right/left fusion is the most common, right non-coronary fusion is 
associated with BAV in patients.  (Siu and Silversides 2010).  
The aortic valves form from a multi-step process as described above. Briefly, 
formation of the valve starts with expression of ECM from myocytes and overlying 
endocardial cells forming the cardiac jelly, migration of cells into the jelly (EMT of 
endothelial and neural crest cells), proliferation and finally elongation of the cusps.  It is 
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therefore logical that multiple mechanisms could explain improper formation of the cusps 
or the etiology of BAV.  Improper migration of the neural crest cells as well as disruption 
in extracellular matrix deposition could be potential etiologies. More specifically, during 
development, disrupted Notch signaling can lead to disruptions in neural crest cell 
patterns resulting in BAV(Jain, Engleka et al. 2011).  
Maintaining proper balance of ECM is important for aorta and valve biology and 
disruption of proper ECM maintenance results in disease. Mature aortic valve structure 
consists of three distinct layers, the fibrosa, spongiosa, and ventricularis. Each layer is 
composed of specified ECM which functions to facilitate a functional valve.  Matrix 
metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) are secreted by 
smooth muscle cells from the aortic wall, fibroblasts, and endothelial cells and regulate 
this balance of ECM. Disruption of this process results in dysfunctional valve cusps. 
Patients with BAV often have decreased aortic elasticity, reduced fibrillin-1 content and 
increased MMP activity supporting a role for disruption of ECM boundaries in valve 
disease (Joziasse, Vink et al. 2011, Abdulkareem, Smelt et al. 2013).  
 
Mitral Valve Prolapse  
In the 2017 American Heart Association report, mitral valve prolapse (MVP) was 
reported as the most common valvular disease. Worldwide, MVP has been shown to 
affect 1 in 40 individuals and for this reason it is a major health care burden (Freed, 
Benjamin et al. 2002). Originally described in the 1960’s, MVP is described as a very 
common Mendelian cardiovascular disorder characterized by the systolic displacement of 
the mitral leaflets above the line of the annulus into the left atrium (Barlow and Bosman 
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1966). Structurally, the leaflets are described as myxomatous, or having increased 
proteoglycans, elastins, and fragmented collagens.  Although often clinically benign, 
MVP is often associated with mitral regurgitation, bacterial endocarditis, congestive heart 
failure, atrial fibrillation and even sudden cardiac death (Freed, Acierno et al. 2003). 
Currently there isn’t any non-surgical treatment for MVP most likely due to lack of 
understanding of the molecular and genetic causes of the disease. This lack of 
understanding combined with the increased population affected by the disease makes 
finding alternative treatments imperative.  
 MVP can be present with other diseases (syndromic) or independently (non-
syndromic). Syndromic MVP can occur with diseases such as in Marfan syndrome while 
non-syndromic MVP is an isolated valve event. Clues from familial studies have shown 
non-syndromic MVP to be a genetically heterogeneous autosomal dominant trait that has 
both sex and age-dependent penetrance. (Freed, Acierno et al. 2003). Increasing evidence 
suggests that congenital valve malformations and disruption of developmentally 
regulated pathways may lead to MVP or myxomatous valve disease later in life.  
MVP is characterized by the billowing of one or both leaflets back into the atria 
during ventricular systole. MVP patients have significantly elongated leaflets, increased 
left atrial size and mitral regurgitation(Freed, Benjamin et al. 2002, Freed, Acierno et al. 
2003). The Framingham Heart study was pivotal because for the first time MVP 
diagnostics was described in detail by echocardiography(Freed, Levy et al. 1999). Until 
recently, published data suggested the prevalence of MVP to be between 5 and 15% even 
up to 35% in some studies (Freed, Levy et al. 1999). Many patients were misdiagnosed 
because clinicians did not understand the proper anatomical dimensions of the mitral 
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annulus. In this study, investigators were able to enroll large numbers of patients with 
familial MVP in order to determine the prevalence of disease in a way that used the 
proper anatomical dimensions of the annulus. Through this study the rate of false positive 
diagnosis has decreased with a prevalence of 1.3% of patients enrolled in the study being 
diagnosed with MVP. From this study a more concrete understanding of diagnosis was 
reached. Additionally, they found that complications that were often associated with 
prolapse such as heart failure, atrial fibrillation, cerebrovascular disease and syncope 
were not higher among subjects with MVP than among those without MVP. 
In healthy mitral valves, the structure of the leaflets plays an important role in 
their proper function. The valve is composed of three distinct layers composed of 
collagens, proteoglycans and elastins. Both mouse and human valves appear to have these 
boundaries although there is slight variation on how many ECM zones exist. Structurally, 
patients with MVP have valves that have undergone myxomatous degeneration, which is 
characterized by excess deposition of proteoglycans and collagens with fragmentation of 
collagens and elastins. In addition to the myxomatous changes that occur in the valve, the 
endothelial boundary is often perturbed (Barlow and Pocock 1985, Anyanwu and Adams 
2007, Bischoff, Casanovas et al. 2016).  Structural changes within the leaflet during 
myxomatous degeneration prevent the leaflets from properly functioning. Over time, the 
constant mechanical pressures felt by the valve lead to elongated mitral chords resulting 
in a flailing leaflet. As a whole, changes in ECM, valvular interstitial cells (VIC) 
activation and valvular endothelial cells (VEC) disruption contribute to the anatomical 
defects that define the myxomatous valve phenotype.  
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Two types of myxomatous degeneration in patients with MVP have been 
described, Barlow’s disease (BD) and fibroelastic deficiency (FED). BD valves tend to be 
thickened with elongated chordae, which sometimes can be thickened fused or even 
calcified. Structurally, these valves exhibit myxoid infiltration, blurring of the structural 
boundaries, and collagen alterations(Barlow and Pocock 1985, Anyanwu and Adams 
2007, Hjortnaes, Keegan et al. 2016).  BD valves are often much larger than normal 
valves with anterior leaflet size at 38mm or greater(Anyanwu and Adams 2007). 
Increased proliferation, and high proteolytic enzyme activity are often seen (Hjortnaes, 
Keegan et al. 2016). The annulus in patients with Barlow’s disease is always dilated and 
often there is sever posterior annular dilation. Calcification of the annulus is sometimes 
found. In FED however the valve tissue is different. FED valves have connective tissue 
deficiencies. Instead of enlarged valves as seen in BD, they often have thinned valves as 
a result of deficiencies in collagen, elastins and proteoglycans with preserved leaflet 
architecture (Anyanwu and Adams 2007). Chordae in these patients tend to be thicker 
with increased elastin and collagen(Hjortnaes, Keegan et al. 2016). Molecularly, FED 
valves have increased elastin, pERK and SMAD2 (Hjortnaes, Keegan et al. 2016). In 
both diseases, activated VICs with increased a-SMA, vimentin, and MMPs are observed.  
 
Genetic Discoveries in MVP 
Determining the genetic contribution of MVP has proved to be a difficult 
undertaking. Prior to the proper diagnosis criteria clinicians based diagnosis on single-
dimensional and eventually 2D echocardiography(Barlow and Bosman 1966). Using 
these parameters, diagnosis for MVP resulted in decreased specificity. It wasn’t until the 
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saddle shaped description of the valve that specificity increased without loss of 
sensitivity(Freed, Levy et al. 1999). With proper diagnosis implemented and the 
phenotypic basis for MVP understood, researchers have been able to make advances on 
the genetic contribution to the disease.  The first locus for autosomal dominant MVP, 
MMVP-1 was mapped in 1999 by Disse et al. Through familial screens, they were able to 
show significant linkage for markers mapping to chromosome 16p(Disse, Abergel et al. 
1999). They also found that among the four large families, linkage could be confirmed on 
only two. This demonstrated the genetic heterogeneity of the disease. In 2003 a study by 
Freed et al discovered a second locus for MVP (MMVP2) mapping to chromosome 
11p15.4 in a large family with inherited MVP(Freed, Acierno et al. 2003). The gene 
involved in X-linked myxomatous valvular dystrophy (XMVD), Filamin A, was 
discovered in 2007 by Kyndt et al. This was the first gene described as being responsible 
for isolated nonsyndromic valvulopathy. With the founding of the first ever transatlantic 
network to study mitral valve disease in 2006 the leading investigators, including 
members of our group, in mitral valve disease all over the world came together to find the 
causal genes involved in non-syndromic MVP. From this collaboration, our group was 
able to identify the first gene for MVP, DCHS1(Durst, Sauls et al. 2015). In this study, 
three large families with inherited MVP were studied. Deep sequencing and linkage 
analysis revealed a region on chromosome 11 as potentially causal. Capture sequencing 
of the linkage interval identified two mutations in the DCHS1 gene among the three 
families(Durst, Sauls et al. 2015). In addition, loss of Dchs1 as being causal was verified 
using a global heterozygous mouse model. This is the first mouse model for MVP 
described and is valuable for future studies of diseases mechanisms.  These major genetic 
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studies have proved invaluable in further understanding the mechanism of disease 





Current evidence from our lab and others in the literature has pointed to an 
association of mutations in genes involved in primary cilia signaling and function with 
cardiac diseases. Primary cilia can be thought of as the antenna of the cell. They have 
been shown to function as mechano-sensors and chemo-sensors to regulate many 
essential pathways(Pala, Alomari et al. 2017). Defects in either motile or non-motile cilia 
have been shown to affect almost all parts of the body, therefore illustrating the 
importance of proper cilia assembly and function. Primary cilia defects can be caused by 
multiple mechanisms such as defect in cilia formation, signal transduction components or 
trafficking.  
Any defect in cilia structure or function is termed a ciliopathy. A large collection 
of ciliopathies have been described including Joubert syndrome (JBTS), Meckel 
syndrome (MKS), nephronophthisis (NPHP) and Bardet-Biedl syndrome (BBS) (Wang, 
Li et al. 2017). Interestingly these ciliopathies also are associated with valve disease 
(Karp, Grosse-Wortmann et al. 2012).  Polycystic kidney disease (PKD), for example has 
been associated with MVP and increased prevalence of aortic aneurysm(Smyth, Snyder et 
al. 2003). Studies have reported that 25% of patients with PKD also have MVP(Lumiaho, 
Ikaheimo et al. 2001). In patients with JBTS, aortic stenosis and BAV have been 
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observed (Karp, Grosse-Wortmann et al. 2012). Bardet-Biedl syndrome (BBS) has been 
linked with both MVP and aortic valve deficiencies(Mukta, Tiwari et al. 2008, Purkait, 
Roy et al. 2012). The mechanism by which cilia dysfunction can cause valve disease and 
whether the valve defects in ciliopathy patients is a primary defect of disrupted cilia is 
not known. Better understanding of this link may provide valuable insight into currently 
lacking diseases etiology.  
 The observation of the cilia is as old as the discovery of the microscope, dating 
back to the times of Antoine van Leeuwenhoek in 1632 (Fuchs 1984). Cilia are 
microtubule-based structures that are composed of an axoneme, basal body, and 
transition zone. The axoneme acts as a molecular highway allowing proteins to traffic up 
and down carrying cargo (Fig 1.2). The basal body, which is originally derived from the 
centrosome of dividing cells, acts to anchor the axoneme in place. Almost all cells have 
either a single non-motile, primary cilium, or multiple motile cilia. These classifications 












Figure 1.2 The Primary Cilia is a Signaling Hub for the Cell. Cartoon of the primary cilia showing 
the axoneme with microtubule structures in green and the basal body in red. Signaling molecules are 
found at the base, along the axoneme, and in the transition zone of the cilia. Proteins traffic to the cilia 
through the trans-golgi network. There they are packaged in vesicles attached to Rab8. Primary cilia 
are composed of a 9 + 0 outer microtubule doublets structure while motile cilia are composed of a 9 + 





Motile cilia, also known as flagella in some cases, can be found as the propelling 
force of sperm, Paramecium, and in the lining of the trachea where they move mucus. 
They can be found in the developing embryo on nodal cells helping to direct fluid flow 
and determine left right laterality. Structurally, motile cilia are described as having a 9+2 
microtubule doublet structure which connects to a central pair of microtubules to the 
axonemal inner and outer dynein arms in order to power the cilia and allow it to move. 
Primary cilia on the other hand are found one per cell and are non-motile. They act as 
molecular signaling antenna which relay information to the cell. The axoneme or antenna 
like structure of the primary cilia is surrounded by a lipid bilayer membrane that is 
continuous with the cell membrane but is enriched with specific proteins involved in 
signaling pathways.  Many major signaling pathways such as Notch1, BMP, TGFB, 
PDGF, Hedgehog, and PKD, have been shown to signal through the primary cilia. 
Receptors from these pathways can be found on the axoneme or within the ciliary pocket 
near the basal body. Loss of the primary cilia structure has been shown to disrupt these 
signaling pathways and leading to changes in downstream gene expression.      
The basal body of the primary cilia has been shown to be the point of localization 
of multiple proteins associated with cilia formation in addition to centrosomal and 
pericentriolar proteins. The ciliary membrane is contiguous with the plasma membrane of 
the cell, so in order to keep signaling compartmentalized, the cilium have a transition 
zone. The transitions zone acts as a gate allowing only proteins involved in cilia structure 
and/or function into the primary cilia.(Garcia-Gonzalo and Reiter 2017)  
Proper cilia function is dependent on proper formation of the cilia, also known as 
ciliogenesis. This process is very complex and requires spatial and temporal expression 
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of a vast repertoire of ciliogenic proteins in a tissue and cell-specific manner. Briefly, 
ciliogenesis is composed of three steps. First, the mother centriole is modified to become 
the basal body at which point it attaches to the plasma membrane through its distal 
appendages. Then the transition zone is formed and finally the rest of the axoneme 
extends out from the cell body. The extension of the axoneme is constructed and 
maintained by the intraflagellar transport (IFT) machinery composed of kinesins, dyneins 
and IFTA and B molecules(Reiter and Leroux 2017). IFT proteins are essential for 
primary cilia structure and function. IFT-A and IFT-B form large platforms transporting 
cargo between the base and tip of the cilium. Ift88 is a component of the IFT-B complex 
along with Ift172, Ift52 and Ift57. Removal of any of these components results in loss of 
primary cilia and loss of response to Hh ligands. However, genetic ablation of the IFTA 
complex does not result in total loss of primary cilia, just abnormal formation. These 
mutants have increased Hh signaling as opposed to the lack of Hh signaling found in 
IFTB mutants. Loss of any of the IFT proteins result in embryonic lethality, polydactyly, 
randomization of the left-right body axis, as well as neural tube closure and patterning 
defects(Murcia, Richards et al. 2000, Haycraft, Zhang et al. 2007).  
One very important pathway involved with proper formation of the primary cilia 
is the exocyst complex. The exocyst is an eight-member protein complex, originally 
discovered in yeast, whose function is essential for exocytosis and ciliogenesis(Lipschutz 
and Mostov 2002). To assemble the primary cilia, the centrosomes of the cells have to 
migrate to the apical membrane. The exocyst helps in this process by assisting in basal 
body migration, membrane docking and fusion of the ciliary vesicles at the site of cilium 
outgrowth. The exocyst also moves proteins to and from the primary cilia through 
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trafficking cargo from the ER-GOLGI membrane. In yeast, mutants of individual exocyst 
members results in failure of vesicles to dock or fuse with the plasma membrane causing 
accumulation of secretory vesicles within the cell. Loss of a key component of the 
exocyst, Sec10, results in loss of ciliogenesis and formation of cysts in kidney cells(Zuo, 
Guo et al. 2009).  
 
Ciliary Signaling  
Many signaling pathways have been shown to be reliant on the primary cilia(Pala, 
Alomari et al. 2017). Various membrane bound receptors, ion channels, transporters and 
downstream proteins localize to the primary cilia. Thus, cilia function as nodal signaling 
hubs that can respond to various biochemical and mechanical cues. Well studied 
pathways such as Notch, TGFβ, hedgehog, and PDGF, for example, rely upon the cilia 
for signal transduction. The niche environment of the primary cilia allows for a unique 
signaling opportunity not found elsewhere in the cell. The ciliary membrane is physically 
restricted and has different protein and lipid composition than the adjacent cell membrane 
(Nachury, Seeley et al. 2010). Additionally, the primary cilia has more membrane per 
area than any other area in the cell and for this reason small signaling changes can have a 
large effect and cell response. Changes in localization of receptors, binding of ligands, 
influx of calcium, and trafficking up and down the cilia have a large impact on the cell. 
All of which would not be possible in another organelle.  
 As shown in Figure 1, trafficking of various proteins to and within the primary 
cilium has multiple functions. By localizing proteins in a spatial and temporal pattern the 
primary cilium acts to coordinate signaling through regulating protein localization, gene 
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expression and protein-protein interactions. Regulation of signaling by the primary cilia 
can be accomplished by movement up and down the axoneme, restriction at the base or 
tip, processing by enzymes within and at the base of the primary cilia and post 
translational modifications. Membrane barriers and the transition zone within the cilia 
help to regulate these functions. In addition, trafficking of proteins through exosomes to 
the primary cilium is important for these processes. The primary cilia can facilitate 
budding of the ciliary membrane at the base in order to release exosomes into the 
extracellular space. In the kidney, these membrane bound vesicles carry important 
biomarkers of disease state (Chacon-Heszele, Choi et al. 2014). The exocyst complex is 
important for the formation of these vesicles along the ciliary axoneme forming cilia-
interacting exosomes. In these ways various signals are relayed through the cell by the 
primary cilia.   
 
Hedgehog signaling  
One of the best studied cilia dependent signaling pathways is the hedgehog (Hh) 
pathway. Although cilia are not required for Hh signaling in Drosophila, they are 
required for mammalian Hh signaling. Members of the hedgehog signaling family have 
been shown to localize to the base of the primary cilia. Receptors patched (Ptch1) and 
smoothened (smo) traffic up and down the ciliary axoneme in response to any of the 
hedgehog ligands; sonic (Shh), indian (Ihh) or desert (Dhh). In the presence of hedgehog 
signal, patched removes repression of smo allowing it to traffic into the ciliary axoneme. 
Once in the axoneme, smo can then interact with Sufu suppressing its activity and 
allowing for processing of Gli family members (Gli1,2, and 3). Gli transcription factors 
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can exist in both full-length active form (GliA) and cleaved repressive form (GliR). In the 
absence of Hh ligand, Gli transcription factors are proteolytically cleaved into repressor 
forms.  
IFT is required for production of GliA and Gli3R (May, Ashique et al. 2005).  
Disruption of the IFT proteins disrupts Hh signaling as well (Haycraft, Zhang et al. 
2007). In mice with deletion of the IFT proteins, the Shh signaling pathway remains 
inactive. This is surprising since loss of cilia results in loss of Gli3 processing into its 
repressive form. However, this suggests that loss of cilia results in insufficient Gli 
processing. In addition, loss of IFT result in loss of Gli2 activation of the pathway. For 
the most part, Gli1 is independent of IFT signaling, except in a positive feedback 
mechanism since Gli1 expression is dependent on hedgehog pathway activation.   
Each Gli transcription factor plays a role in a developmental and tissue specific 
manor. Gli1 is primarily an activator of the Hh pathway. Transcription of Gli1 leads to 
further activation of the pathway through activation of both Gli2 and Gli3. This feed-
forward loop results in increased transcription of Gli1. Gli1 has been shown to regulate 
downstream transcription of extracellular matrix genes. For example, Gli1 activation 
leads to increased expression of collagen 1 as shown in pancreatic cancer studies (Duan, 
Ma et al. 2014). In addition, Gli1 can bind to an enhancer element on osteopontin (OPN) 
regulating its expression (Pritchett, Harvey et al. 2012).  
 The other major activator of the Hh pathway is Gli2. Gli2 activator is formed by a 
cilia and smo dependent process. Upon HH interacting with Ptch1, Ptch1 is removed 
from the cilia and allows Smo to enter the cilia. In the presence of Hh, Gli2 in complex 
with Gli3 and SuFu are trafficked to the tip of the cilia where they accumulate. At the tip 
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of the cilia this complex dissociates allowing Gli2 to become active. In models of fibrosis 
such as in the liver, Gli2 has been shown to be an important regulator of fibrotic signals. 
Gli2 is an upstream regulator of Sox9 and through this regulation is responsible for 
osteopontin expression in hepatic stellate cells (HSC). The HSCs become activated into 
proliferative myofibroblasts in response to injury and begin migrating into the 
surrounding parenchymal cells. Much like in a myxomatous valve they then begin to 
secrete ECM such as collagen 1 which is damaging to the tissue structure (Pritchett, 
Harvey et al. 2012). 
Gli3 is critical for basal suppression of the Hh pathway. Gli3 repressor is formed 
in a protein kinase A (PKA) dependent manor through proteolysis. When cleaved, N-
terminus acts as transcriptional repressor. Gli3 is negatively regulated by GPR161 which, 
in the absence of Hh signal, activates Gαs, thereby activating adenylyl cyclase increasing 
levels of cAMP and finally activating PKA. PKA then goes on to phosphorylate sites of 
Gli3, targeting it for proteolysis by βTrCP/Cul1. Gli3R then moves into the nucleus and 
suppresses Hh target genes. Binding of Hh to its receptor Ptch1 facilitates the removal of 
Gpr161 from the cilia thereby preventing further downstream processing of Gli3 and 
allowing it to remain in its full length active state. TULP3 regulates the localization of 
Gpr161 in the cilia. (Mukhopadhyay and Rohatgi 2014) 
The HH pathway has many proteins which act to further enhance or repress the 
pathway. For example, Gli3 regulates expression of Gli1, which regulates expression of 
Ptch1. (Haycraft, Banizs et al. 2005) Loss of Polaris, also known as Ift88, results in 
increased Gli3A suggesting inefficient processing. Gli3R is able to repress the Hh 
pathway regardless of the presence or absence of Ift88; however, there is increased Gli3A 
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in the absence of Ift88. This suggest that small amounts of Gli3R is able to repress the 
pathway even in the presence of Gli3A. Experiments have shown that smo accumulates at 
the base of the cilia within 1hr of treatment with Shh. However, localization of smo to the 
primary cilia is not sufficient for Hh signaling. Experiments with loss of retrograde 
ciliary trafficking results in Hh insufficient phenotypes (Bangs and Anderson 2017).  
 
Receptor Tyrosine Kinases 
Reviewed in (Christensen, Clement et al. 2012), receptor tyrosine kinases such as platelet 
derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR), 
insulin-like growth factor 1 receptor (IGF1R), and fibroblast growth factor (FGF) have 
all been expressed at the axoneme of  primary or motile cilia. RTKs can interact with 
other signaling pathways and have been implicated in cross talk with g-protein coupled 
receptors to regulate ECM production. Disruption of this process results in many human 
health problems and diseases that, at least in part, mimic defects observed in patients with 
known ciliopathies.  
Platelet derived growth factor or PDGF is a receptor tyrosine kinase that is 
upregulated upon starvation and cilia formation (Clement, Mally et al. 2013). PDGFRα 
localizes to the cilia while PDGFRβ localizes along the cell membrane. PDGFRα 
signaling has been implicated in different types of cancers and is associated with fibrotic 
diseases (Christensen, Clement et al. 2012). In some cell types localization to the primary 
cilia is necessary for receptor dimerization and downstream signaling. PDGF signaling 
through the cilia can regulate cell cycle and cell migration. Stimulation of PDGFRα  
leads to activation of AKT and MEK1/2-ERK1/2 resulting in localization of the Na+/H+ 
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exchanger, NHE1, to the leading edge of the cell which is necessary for cell 
migration(Clement, Mally et al. 2013). Genetic deletion of PDGFRα and β in mice 
results in loss of epicardial EMT, increased fibrosis and loss of vascular smooth muscle 
cell migration during vascular formation (Smith, Baek et al. 2011, Gallini, Lindblom et 
al. 2016).  
 
Calcium/PKD/ERK 
Polycystic kidney disease 1 (Pkd1) and 2 (Pkd2) have been well studied for their causal 
mutations in about 90% of patients with autosomal dominant polycystic kidney disease 
(Avasthi, Maser et al. 2017). Mutations in either PKD1 or PKD2 result in loss of 
polycystins to the ciliary membrane. Polycystin-2 interacts with polycystin 1 to regulate 
calcium signaling. Pkd1 regulates G-protein signaling pathway through binding to Gα 
subunits. Pkd2 functions as a calcium channel that is activated through bending of the 
primary cilia(Pala, Alomari et al. 2017). Pkd1 and Pkd2 dimerize and together function 
with ryanodine receptors to mediate transduction of extracellular mechanical stimulus 
into a calcium signaling response (Nauli, Alenghat et al. 2003). In addition to developing 
PKD, mice with these mutations have a high penetrance of cardiac malformations (Wu, 
Markowitz et al. 2000).  One study looking at cardiac abnormalities in patients with 
autosomal dominant polycystic kidney disease (ADPKD) found 25% of the patients with 
PDK had MVP (Lumiaho, Ikaheimo et al. 2001). In addition to MVP, aortic regurgitation 
and left ventricular hypertrophy have been documented in patients with 
ADPKD(Hossack, Leddy et al. 1988, Martinez-Vea, Bardaji et al. 1999). These data 
suggest a potential role for cilia signaling in patients with MVP.  
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Notch  
Notch signaling is very important during development in patterning the embryo. 
Notch receptors have been shown to signal though the primary cilia by regulating 
cleavage of Notch  (Ezratty, Stokes et al. 2011, Pala, Alomari et al. 2017).  Notch 
signaling occurs when ligands Delta or Jagged bind one of the four Notch receptors 
(Notch1-4). Upon binding, Notch receptor is proteolytically cleaved via γ-secretase, 
resulting in the formation of Notch intracellular domain (NICD). NICD translocates to 
the nuclease and regulates target genes such as Hes and Hey(Tran, Sharma et al. 2014). 
Evidence for the primary cilia in regulating Notch signaling has previously been shown 
in skin and cardiac development. In skin development, Notch 3 signals through the 
primary cilia to regulate epidermal differentiation (Ezratty, Stokes et al. 2011). The 
primary cilia functions in processing Notch to generate NICD. Presenilin-2, the enzyme 
responsible for Notch cleavage, localizes to the basal body and its activity has been 
shown to be dependent on the primary cilium.  
Prior to ligand binding Notch receptor undergoes endosomal sorting either for 
recycling to the plasma membrane or for lysosomal degradation. Disruption of this 
endosomal sorting complex results in over activation of Notch. Ciliary function is linked 
to endosomal recycling and exosome formation and studies have shown disruption of 
Notch recycling leads to increased activation of the pathway. In zebrafish and human cell 
lines, loss of basal body proteins leads to an increase in expression of Notch targets 
(Leitch, Lodh et al. 2014). It is thought that Notch trafficking to the cilia is controlled by 
Bardet-Biedl syndrome (BBS) proteins. Loss of BBS proteins results in aberrant 
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trafficking of the receptor through late endosomes to lysosomes and impaired recycling 
of the Notch receptor (Leitch, Lodh et al. 2014).  
Notch1 signaling also plays a role in cilia length regulation (Lopes, Lourenco et 
al. 2010). Cilia length is a critical regulator of cilia function. Reduction of Notch 
signaling in zebrafish results in shorter cilia while hyperactivation produces longer cilia. 
In addition, changes in motile cilia length in the zebrafish node/ Kupffer’s vesicle (KV) 
result in laterality defects.  
 
Cilia in the heart 
Many well studied ciliopathies have been shown to play a role in CHD and 
cardiovascular disease. Large scale mutagenesis screens showed that cilia play a role in 
left right patterning of the heart as well as cardiac looping(Li, Klena et al. 2015). In 
addition to motile cilia, primary cilia have also been implicated in heart development and 
have been shown to cause CHD when disrupted. Some well-studied CHDs such as 
atrioventricular septal defects, left- right patterning, heterotaxy, conotruncal defects, and 
left ventricular obstruction have been linked to defects in cilia function (Klena, Gibbs et 
al. 2017). Defects in Hh signaling in the second heart field derived structure, the dorsal 
mesenchymal protrusion (DMP) lead to atrioventricular septal defects (AVSDs)(Briggs, 
Burns et al. 2016). Primary Cilia Dyskinesia (PCD) for example is a ciliopathy that 
results in defects of ciliary motility. Predominantly PCD results in difficulty with 
mucociliary clearance and organ laterality defects(Harrison, Shapiro et al. 2016). Links 
have been made between PCD and CHD because 50% of patients with PCD have organ 
laterality defects and 3.5-6% have cardiovascular malformations(Kennedy, Omran et al. 
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2007).  In addition, the tectonic protein 3 (Tctn3) localizes to the transition zone of the 
cilia and forms a large complex with several ciliopathy-associated proteins. Disruption of 
this protein results in incorrect heart looping(Wang, Li et al. 2017).  
The first description of cilia in the heart was in 1969 by Rash et al. (Rash, Shay et 
al. 1969). Through electron microscopy screens they were able to identify cilia in chick, 
rabbit, mouse and lizard embryos in nonmitotic cardiomyocytes. Later in 2008, Slough et 
al published a more thorough description of cilia in the heart (Slough, Cooney et al. 
2008). They show cilia expression in the developing heart at E9.5 in both myocardium 
and cardiac endothelium. They also show cilia on the endothelium of the developing 
endocardial cushions although staining is not very clear. Additionally, at E12.5, they 
show cilia present on the ventricular surface of trabeculations as well as in the developing 
valves. Global deletion of Kif3a (a critical motor protein needed for driving ciliogenesis) 
results in failure of cardiac cilia to form and disrupted formation of endocardial cushions 
with decreased cellularity. These studies however lack data identifying the effects of cilia 
loss into postnatal valve development, due to embryonic lethality of the global knockout. 
They also suggest that the cilia function as mechanosensors since they are expressed 
during the stage of heart development, which rely on sensing blood flow for 
morphogenesis. They hypothesize that cilia function in different ways during different 
stages of cardiac development. Although this paper was not a complete description of 
cilia in the heart at all stages of development they provide the first evidence that primary 
cilia are present and may be playing a role in cardiac development.  
In order to determine the genetics that may be involved in congenital heart 
disease, large scale ENU screens were completed by Cecilia Lo’s lab(Li, Klena et al. 
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2015). Screening of 87,355 chemically mutagenized mice was done to reveal 218 CHD 
mouse models. From this screen 34 cilia related genes were discovered. The mutations 
were in genes that regulated ciliogenesis, ciliary trafficking, and cilia signaling. Of these 
genes some were found to be mutated in mice with laterality defects suggesting motile 
cilia while others were found to be mutated in mice without laterality defects suggesting 
non-motile primary cilia. Comparably, genes found in this screen were found to be 
similar to those found in a study of human patients with CHD(Zaidi, Choi et al. 2013). 
Of the mutations recovered, 12 were found in genes that are in cilia transduced 
signaling pathways suggesting that ciliary signaling in the heart is important for proper 
development. Major signaling pathway genes were found also found such as genes 
mediating Hh, TGFβ, and Wnt signaling. The discovery of mutation in genes regulating 
vesicular trafficking is also of note since vesicular trafficking and receptor recycling play 
important roles in regulation of cell signaling. Mutations were found in Dynamin 2, 
Ap2b1, Ap1b1 and others which have been shown to mediate endocytic receptor 
recycling(Li, Klena et al. 2015, Klena, Gibbs et al. 2017).  
 Strong evidence from the literature suggests primary cilia as a common link 
among valve diseases. Genetic evidence from our lab and others suggests that defects in 
primary cilia structure and/or function result in valve disease. This thesis work aims to 
better understand the relationship between primary cilia signaling and valve disease. 
Starting with a hypothesis that primary cilia are important for valve development and 
using this information to inform patient-based studies, we were able to discover a novel 
gene for MVP and potential mechanism for BAV. The following chapters are an 
illustration of this work.  
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BAV is one of the most common cardiac diseases affecting 0.5-2% of the population. It is 
the most common congenital heart disease responsible for increased morbidity and 
mortality in infants.  Currently the only treatment option is surgery to replace the 
damaged tissue. Complications of BAV are severe, ranging from aortic stenosis to aortic 
rupture and calcific aortic valve. Familial studies have provided evidence that BAV 
might be linked with autosomal dominant inheritance however the mechanistic 
underpinnings are unclear.  
 BAV occurs when only two of the three aortic cusps form properly during 
embryonic development. Often this occurs in the presence of a raphe, or a fusion line 
between what would normally be two cusps. Developmentally, the aortic cusps form 
from anterior second heart field, endocardially derived and neural crest cells which 
migrate into the cardiac jelly early during development. Signaling cues from the 
surrounding myocardium as well as endocardial cells help to orchestrate this process. 
Patients with BAV often have myxomatous aortic valves and are likely to present with 
other diseases such as aortic aneurism which is caused by defects in ECM structure of the 
aorta. Therefore, it is likely that defects in cell migration or extracellular matrix 
production is the causal factor in the development of BAV.  
 To date, only a few genes have been identified in pedigrees and it is clear that no 
single gene-model explains BAV inheritance, thus supporting a complex genetic network 
of interacting genes. However, patients with rare syndromic diseases that stem from 
alterations in the structure and function of primary cilia (“ciliopathies”) exhibit BAV and 
aortic stenosis (AS) as frequent cardiovascular findings, suggesting that primary cilia 
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may play a broad role in disease etiology.  This contention is supported by our data, 
which demonstrate that primary cilia are expressed on undifferentiated aortic valve 
mesenchymal cells during embryonic development and are lost as these cells differentiate 
into collagen-secreting fibroblastic-like cells. This suggested a role for primary cilia in 
restraining aortic valve interstitial cell (aVIC) differentiation, which was tested by 
genetically ablating cilia through Cre-mediated excision of Ift88, a critical ciliogenic 
gene. Loss of Ift88 resulted in abrogation of primary cilia and increased fibrogenic ECM 
production.  Consequentially, stratification of zonal ECM boundaries normally present in 
the aortic valve were lost and a highly penetrant BAV phenotype was evident at birth. 
These data support cilia as critical for restraining ECM production during aortic valve 
development and broadly implicate these structures in the etiology of BAV disease in 
humans.  
Results 
Temporal-Spatial Analyses of Primary Cilia During Aortic Valve Development 
In order to determine if cilia are expressed in the aortic valve a developmental expression 
panel was done. Primary cilia expression was determined by immunohistochemical stains 
for ciliary markers which were then imaged using high-resolution confocal microscopy. 
From this study we showed that primary cilia are expressed throughout development on 
the developing VICs. Cilia are expressed on nearly all valve cells early in development 
(E11.5) at which they are short protrusions averaging around 0.5-1.0µm in length 
(Fig2.1). As the valve begins to develop further (E13.5-E15.5) cilia are largely absent 
form VECs but remain on almost all VICs. By late developmental and postnatal time 
points the expression of the primary cilia appears to be localize to specific regions of the 
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valve largely the tip and atrialis regions. At this stage, the cilia length appears to have 
peaked between 2-2.5µm in length. At adult time points the majority of the primary cilia 
are completely absent from the valve (Fig2.1).  
The localization of the primary cilia to specific regions of the valve during 
development could give insight into their role. During early development, when nearly all 
cells express cilia, the ECM is composed mainly of proteoglycans. As the valve develops 
it begins to stratify into different layers and express collagens. This division of matrix 
matches what we see with expression of the primary cilia. As shown in Figure 2, primary 
cilia localize to areas high in proteoglycans. Early in development (E11.5) when the 
valve is composed mainly of proteoglycans such as versican, primary cilia re-expressed 
on nearly every interstitial cell. When the valve begins to elongate and mature (E17.5 and 
P0) the cilia are still present in areas highly expressing proteoglycans but are largely 
devoid in areas high in collagen expression (Fig 2.2). Quantification of cilia length at 
postnatal day 0 shows increased cilia length in versican rich regions when compared to 
collagen rich regions. This expression pattern could be explained in two ways, either the 
matrix is negatively regulating the expression of the cilia or the cilia are dictating the 




Figure 2.1: Spatial and Temporal Expression of Primary Cilia during Aortic Valve Development. 
(A) IHC for the ciliary axoneme (green), basal body (red), and nuclei (blue) show expression of cilia 
throughout valve development. Cilia appear shorter during early embryonic stages and longer right 
before and after birth. Arrow indicate valvular endothelial cells devoid of cilia (B) Quantification 
of cilia length showing increased expression of cilia during embryonic development and decreased 




 Figure 2.2 Primary Cilia Co-localize with Proteoglycans During Development 
(A) IHC for the ciliary axoneme (green), collagen (red, top) versican (red, bottom), and nuclei (blue) 
show expression of cilia throughout development. Cilia appear to be expressed highly in areas rich 
in proteoglycans and less in areas high in collagen. C= conal cushions, RC= right coronary, LC= 
left coronary, NC= non-coronary, Ao= aorta. (B) High magnification images of axonemes (green) 
and collagen/versican (red). Arrows depict collagen rich regions expressing shortened cilia. (C) 
Quantification of cilia length in both versican and collagen rich regions shows decreased average 








This differential expression pattern could be indicative of a potential role for cilia during 
development. Previous research has shown that biomechanical forces are important for 
proper valve formation. It is therefore possible that the cilia present on the VICs are 
sensing the changes in interstitial fluid flow within the tissue and acting as 
mechanosensors to orient the proper formation of the valve.  Although the function of 
primary cilia as mechanosensors on non-epithelial cells is poorly known, prior work has 
shown this as a possibility(Nauli, Jin et al. 2013, Nguyen and Jacobs 2013). In addition, 
cilia have also been shown to function as chemosensors, which respond to growth factors 
such as Notch, Wnt, Pdgf, and Hedgehog. One study on hedgehog signaling in the valve 
showed normal cushion development in sonic hedgehog and smoothened Tie2 
conditional knockout mice (Goddeeris, Rho et al. 2008). This is not surprising as 
previous research has shown sonic (Shh) and indian  (Ihh) hedgehog are not expressed in 
the developing valves (Bitgood and McMahon 1995). They do show however that desert 
hedgehog (Dhh) is expressed in the developing endocardium of the cushion. Therefore, 
hedgehog signaling may still be playing a role in the development of the cushions 
through Dhh and non-canonical hedgehog signaling. To determine if hedgehog signaling 
was playing a role we began by preforming RT-PCR on cushion mesenchyme, looking 
for expression of pathway members (Fig 2.3). Both receptors for the pathway, patched 
and smoothened as well as downstream transcription factors, Glis, were expressed by 
mouse atrioventricular cushion cells. Notably, the ligands for the pathway Shh, Ihh and 
Dhh were not expressed. This was to be expected as previous research shows no 
expression of Shh and Ihh in the valves and expression of Dhh only in the VECs(Bitgood 
and McMahon 1995) 
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Figure 2.3. Hedgehog Signaling Components are Expressed in VICs. RT-PCR done 
on  mouse AVC cells. RNA was extracted from AVC cells and reverse transcription was 
done to get DNA. Gels show expression of Hh receptors smoothened and patched. 
Expression of the downstream Gli transcription factors are also observed. No expression 













 Expression of smoothened was confirmed by 3D-immunohistochemistry (3D-IHC) on 
aortic valve interstitial cells during development. Data show smoothened on the axoneme 
of the primary cilia which is indicative of active Hh signaling (Fig 2.4 A). In the absence 
of Hh ligand, patched represses smoothened and prevents its entry into the primary 
cilium. In the presence of Hh ligand, during active signaling, patched relieves its 
repression and smoothened is allowed to enter the primary cilia. In addition, IHC staining 
shows nuclear expression of downstream Gli3 transcription factor at postnatal day 0 (Fig 
2.4 B). These data suggest that active Hh signaling is occurring in the aortic valves 







Figure 2.4 Active Hedgehog Signaling Occurs in the Developing Aortic Valves. A. 
3D-IHC showing expression of smoothened (red) on the axoneme (green) of the primary 
cilia. Arrow heads show activated smoothened. B. IHC showing nuclear localization of 
Gli3 (red) in P0 aortic valves. RC=right coronary, LC=left coronary, NC=non-coronary, 











To determine if cilia are functionally important a mouse model with valve specific cilia 
deletion was used. One model for cilia ablation is the Ift88 conditional mouse created by 
Brad Yoder’s lab (Haycraft, Zhang et al. 2007). Ift88 is an intraflagellar transport protein 
that acts as a scaffold for vesicle transport up and down the ciliary axoneme. It has been 
shown to be essential for the formation and maintenance of primary cilia. Loss of Ift88 
results in either total deletion or very short ciliary axonemes and global deletion is early 
embryonic lethal (Pazour, Dickert et al. 2000, Veland, Awan et al. 2009). Since global 
deletion of primary cilia is embryonic lethal, the cardiac specific Nfatc1 cre mouse was 
used to breed with the conditional Ift88 mouse. The aortic valves are composed of 
anterior second heart field progenitors, endocardial and endocardial derived cells as well 
as a small population of migrating neural crest cells (Leung, Liu et al. 2015, Koenig, 
Lincoln et al. 2017). Therefore, the Nfatc1 cre mouse was used in order to produce a 
valve specific deletion of Ift88.  To confirm cilia expression was gone in the conditional 
knockout animals, immunohistochemical stains for primary cilia were performed. Stains 
show loss or very short axonemes in conditional knockout animals and normal cilia 
structure in the wild type animals (Fig 2.5). 
To confirm cilia expression was gone in the conditional knockout animals, 
immunohistochemical stains for primary cilia were performed. Stains show loss or very 
short axonemes in conditional knockout animals and normal cilia structure in the wild 




Figure 2.5 Cilia Expression is Lost in Ift88f/f Nfatc1cre+ Mice. IHC showing 
loss of cilia expression in conditional knockout animals. Axonemes in green and basal 
bodies in red. Arrows pointing to cilia expression; arrow heads pointing to loss or 














Structural defects were observed in conditional knockout valves. Histology 
showed merging of hinge regions between the right and non-coronary leaflets indicative 
of a bicuspid valve (Fig 2.6). Three-dimensional reconstruction showed the formation of 
two instead of three cusps in the conditional knockout when compared to litter mate 
controls. This bicuspid phenotype was observed in a high percentage of all knockouts 
examined, about 68 percent, with about ten percent showing a raphe like fusion. In 
addition, volume measurements were taken and the right coronary leaflet of the 
conditional knockout was significantly larger when compared to wild type controls.  
Since increased extracellular matrix is one of the hallmarks of diseased valves, we 
tested whether alterations in ECM production were evident in the fused NfatC1/Ift88 
aortic cusps. Immunofluorescence staining shows increased expression of ECM protein. 
At postnatal day 0 conditional knockouts have increased expression of versican, and 













Figure 2.6 Conditional deletion of Ift88 results in BAV. H and E staining 
showing fusion of right coronary (RC) and non-coronary (NC) leaflets in the conditional 
knockout. LC=left coronary. 3D reconstructions show BAV phenotype in conditional 


















Figure 2.7 Ift88 Conditional Knockout Aortic Valves Have Increased ECM 
Expression. (A) IHC for versican showing increased expression in the conditional 
knockout. (B) IHC for collagen1a1 showing increased expression in the conditional 















Additionally, this bicuspid phenotype did not appear to be caused by increased 
proliferation since there was no significant difference in Ki67 or Ph3 positive cells in 
conditional knockouts when compared to controls (Fig 2.8). When total cell number was 
counted, there was also no significant difference between conditional knockout and wild 
type. These data suggest that loss of primary cilia in the aortic valve does not result in 
increased proliferation or migration of cells into the leaflet.  
In addition to seeing increased extracellular matrix, we observed decreased cell 
density in the Nfatc1cre+; Ift88f/f mice. Observations from H and E staining showed less 
cells within specific regions suggesting that the enlarged aortic valve could be caused by 
increased matrix (Fig 2.9). Nuclei from a specified region within the valve were counted 
in order to determine nuclear density within the tissue. These data indicate that the valve 
ECM is expanding and this change can explain the increased valve size seen in the 













Figure 2.8 Loss of Primary Cilia does not Affect Proliferation or Infiltration of 
Cells. A. IHC for Ki67 and phosphohistone H3 showing proliferating cells (red) and 
Mf20 marking the myocardium (green). B. Quantification of A showing no significant 
difference in proliferating cells or total cell number. Students t test was used to determine 















Figure 2.9 Conditional Ablation of Primary Cilia Results in Decreased Cell Density. 
A. H and E of P0 aortic leaflets show decreased nuclei density at both the base and tip of 
the right, right non-coronary leaflet (RNC). B. Quantification of A showing decreased 















Increased proteoglycans and fragmented collagen is indicative of diseased valves 
so we next looked at the adult mice to determine if loss of primary cilia leads to adult 
aortic disease. Staining’s showed similar trends to that observed during postnatal time 
points. Nfatc1cre+;Ift88f/f mice had increased expression of collagen and versican with 
enlarged myxomatous cusps (Fig 2.10). Quantification of cell density also showed 
decreased cell density in conditional knockout cusps (Fig 2.11). Cells within a specified 
area of the valve were quantified and conditional knockout valves has increased ECM 
expression and decreased cell density.  
Next, we wanted to look at the type of collagen produced in these valves to 
determine if collagen synthesis was being affected. To do this herovici stains were done 
on adult conditional knockout and wild-type control valves. Data show increased 
expression of newly synthesized collagen and decreased expression of full length mature 















Figure 2.10 Loss of Primary Cilia results in myxomatous adult BAV. IHC, left and 
middle panel, show collagen and versican staining in red and mf20 myocardial staining in 
green. Movat’s pentachrome stain, right panel, shows mixing of ECM boundaries with 















Figure 2.11 Loss of Primary Cilia Leads to Decreased Cell Density in Adult Aortic 
Valves. A. IHC for versican (red) and nuclei (blue) show less nuclei in the conditional 
knockout compared with control. B. Quantification of A showing significant difference 


















Figure 2.12 Loss of Primary Cilia results in decreased mature collagen expression. A. Herovici’s 
stains showing mature collagen in red and immature collagen in blue. Conditional knockout valves 
have decreased full length collagen when compared to controls. B. Quantification of A, there is a 
statistically significant decrease in full length collagen in the conditional knockout valves when 














This, along with the previous data, suggest that primary cilia are needed during 
development to regulate cell maturation and extracellular matrix production. The 
Herovici staining showed decreased expression of full length collagen suggesting that 
loss of primary cilia in valve cells during development results in a high turnover or 
fragmentation of collagen.  
Discussion 
The genetic underpinnings of BAV are currently not well understood. These studies are 
the first description of primary cilia expression in the aortic valves during development. 
These data show that primary cilia are important for proper valve development and may 
play a prominent role in the development of BAV. Primary cilia act to promote VIC 
differentiation and therefore proper ECM production. In this way the primary cilia act to 
direct valve architecture during development allowing for proper function. When primary 
cilia or signaling through the primary cilia is prematurely lost, accelerated  differentiation 
occurs. This results in VICs that are overproducing ECM, which ultimately results in 
myxomatous BAV.  
Future studies are needed to determine the molecular mechanisms that underlie 
this phenotype although evidence suggest that primary cilia regulate ECM production 
though activation of the dessert hedgehog signaling pathway. Previous research shows 
Gli transcription factors play a role in regulating ECM gene expression such as collagen 
(Bolanos, Milla et al. 2012, Amano, Densmore et al. 2014, Duan, Ma et al. 2014). To 
better understand the role primary cilia may be playing in valve development and disease 
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we could perform RNA seq on isolated valve leaflets both wildtype and conditional 
knockout mice at early embryonic times such as E13.5 and at postnatal time points such 
as P0. These data could be informative as to when this change in matrix is occurring and 
if the genes in the hedgehog pathway are involved. Additional experiments looking at 
target genes of Gli transcription factors could give insight into what genes the Gli factors 
are regulating in the aortic valves. Chip-Seq experiments with pulldown of Gli3 and 
sequencing of its targets would show what genes Gli3 is regulating.  In addition, looking 
at non-canonical hedgehog signaling may be informative. Studies have shown hedgehog 
ligands signaling through other pathways independent of Gli transcription factors (Fei, 
Sanchez-Mejias et al. 2012). 
 In order to further investigate the hedgehog signaling pathway other conditional 
knockout mice could be used.  Analysis of the smoothened conditional knockout mouse 
would help to determine if the hedgehog signaling pathway plays a role in this valve 
phenotype. If smoothened conditional mice develop BAV then it would provide evidence 
that this pathway plays a role. In addition, some in vitro studies could be performed by 
treating mouse atrioventricular cushion cells with Dhh to see if Gli processing is affected. 
Culturing of VICs from conditional knockout and control valves could be used also for 
treatment with Dhh followed by western blots looking at Gli processing. Cyclopamine, an 
inhibitor of the Hh signaling pathway could be used to treat the control valve tissue in 
order to show that inhibition of the Hh signaling pathway is regulating this change in the 
Ift88 conditional mice.  
 Additional pathways may also play a role in this process. Cilia have been shown 
to regulate many important developmental pathways such as Wnt, TGFβ, PDGF and 
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Notch. Since Notch gene mutations have been implemented in the development of BAV 
this pathway might be good to investigate. Histological stains for cleaved notch in 
knockout and wildtype mice would show if notch cleavage is affected in this model.  The 
PDGFR pathway may also play a role in the BAV phenotype we observed. PDGFα 
localizes to the primary cilia and can play a role in ERK signaling. In addition, PDGF is 
regulated by TGFβ which plays an important role in valve development and the 
progression of myxomatous disease (Narine, De Wever et al. 2006, Maredia, Greenway 
et al. 2017, Peng, Yan et al. 2017). There is also a strong association in pregnant mothers 
of circulating lymphatic PDGF with offspring that had congenital heart disease(Steurer, 
Norton et al. 2017). To test this hypothesis, leaflets from P0 Ift88 conditional knockout 
and wildtype valves would be dissected and western blots would be done probing for 
PDGFα and phosphorylated PDGFα as well as other members of the pathway such as 

























CHAPTER 3: A DEVELOPMENTAL BASIS FOR MITRAL VALVE 
























Until recently, primary cilia were thought to be vestigial evolutionary remnants 
with no persisting function. Recent evidence however has shown that this is not true. 
Genetic discoveries have linked mutations in cilia genes to a spectrum of rare syndromic 
diseases known as ciliopathies. There is a wide range of organs affected by these 
ciliopathies such as heart, kidney, skeletal or neurological tissues. One particularly 
interesting finding shows a 25% comorbidity of autosomal dominant polycystic kidney 
disease ADPKD and MVP. In addition, these diseases have a very similar 
characterization of increased proteoglycan deposition as well as disorganization and 
fragmentation of the collagen and ECM.  This co-morbidity of ADPKD and MVP, as 
well as their similar pathological features suggests that perhaps MVP could be a disease 
of altered primary cilia function.  
 To begin to understand the relationship between mitral valve development and 
disease we started by asking the question, “Are primary cilia expressed during 
development on mitral valve tissues?”. Previous reports showing primary cilia in the 
mitral valve have been vague and unclear. In order to determine if primary cilia were 
expressed throughout development immunohistochemical stains for the axoneme and 
basal body were done.  
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Figure 3.1 Primary Cilia are Expressed During Mitral Valve Development. A. IHC 
for primary cilia staining axonemes (green) basal bodies (red) and nuclei (blue) show 
expression of primary cilia on VICs. Cilia expression is lost at adult stages. B. 
Quantification of grouped cilia length shows ciliary length increases during development 




Expression patterns showed multiple interesting things. Cilia are expressed on nearly 
every cell very early in development from E9.5-E11.5 (Fig 2.1A). They are expressed on 
nearly all VICs and some VECs and are short in length averaging between 0.5 and 1µm 
in length (Fig 3.1).  As the cushion enters its differentiation and proliferation stages, 
around E13.5-15.5 the cilia are expressed solely on VICs with about 85 percent of cells 
expressing cilia. In addition, cilia at these stages are longer with their grouped cilia length 
peaking around 1.5µm. As the valve continues to develop during later embryonic 
development and postnatal time points its cilia reach peak length at around 2µm (Fig 
3.1B). At adult stages, cilia expression is almost completely gone. Cilia length has been 
shown to change during development in the kidney and is necessary for signaling during 
development.  Interestingly, ciliary expression at theses time points appear to be localized 
to specific regions within the valve. Cilia length has been shown to vary by cell type 
suggesting a necessity for different lengths during development(Avasthi, Maser et al. 
2017). Ciliary length is regulated by the localization and quantity of IFT protein as well 
as other proteins necessary for cilia assembly (Avasthi, Maser et al. 2017). Kinases have 
been shown to regulate cilia length as well, acting as sensors to regulate this process. In 
the kidney, cilia length increases during development (Saraga-Babic, Vukojevic et al. 
2012). Data show that embryonic cilia in the collecting ducts are around 0.55µm long, 
while those from postnatal cells were significantly longer at 1.23µm (Saraga-Babic, 
Vukojevic et al. 2012). This change in length is also observed in the nephron, with length 
changing from 0.81µm to 3.01µm (Saraga-Babic, Vukojevic et al. 2012). This is similar 
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to what was observed in the mitral valve during development (Fig 3.1). This change in 
cilia length provides support for cilia playing a role during embryonic development.  
 To show that cilia from VECs were not being broken off or missed during 
sectioning, other endothelial cell types were examined. As shown in figure 3.2, 
ventricular and interventricular septum endocardial cells express primary cilia. These 
data suggest that primary cilia are expressed on the ventricular and septal endocardial 
cells but not valvular endocardial cells during development.  
 To determine if the cilia expression found in mice also was found in humans, fetal 
human hearts were examined. Immunohistochemical stains for primary cilia were 
performed on 10 weeks and 13 weeks fetal human hearts. Staining shows primary cilia 
present on the interstitial cells at both stages (Fig 3.3).  Analysis of adult human mitral 
valve tissues also follows a similar pattern as in mice with very few if any cilia observed 














Figure 3.2. Primary Cilia are Expressed on Ventricular and Septal Endothelial 
Cells. IHC showing expression of axonemes (green) and basal bodies (red) on endothelial 
cells of the interventricular septum (A) and left ventricular wall (B) in developing E17.5 
(A) and P0 (B) hearts. E17.5 high magnification images of the interventricular septum 
(A’) and (B’) and P0 high magnification images of the left ventricular wall (A’’) and 




Figure 3.3. Primary cilia are Expressed on Fetal Human Valves. IHC (left and middle 
panel) shows expression of acetylated tubulin (green) and gamma tubulin (red) on 10 
week and 13-week fetal valve tissue. 3D reconstructions of IHC (right panel) shows 











To better understand if primary cilia correlate with regions of ECM stratification, 
IHC was preformed using antibodies against proteins that demarcate specific ECM 
boundaries within the mitral valve. ECM expression during development stratifies into 
specific regions of the valve that appeared to be localized with the primary cilia. To 
determine if ECM and cilia were co-localizing to specific regions within the valve we 
stained for two well documented ECM proteins, versican and collagen1a1.  
Early during development, the AV cushions are composed mainly of 
proteoglycans with little collagen expression. At this stage as shown in figure 3.1, the 
cilia are short but expressed on nearly every cell. As the valve ECM begins to mature the 
cilia appear to localize to specific regions in the valve mainly expressing versican. At 
postnatal day 0 cilia are highly expressed in proteoglycan (versican) rich regions and are 
notably absent in collagen expressing regions (Fig 3.4C). When quantified, the 
percentage of ciliated cells in versican rich regions were significantly higher than the 
percentage of ciliated cells in the collagen rich regions (Fig 3.4C). In addition, cilia that 
are expressed in versican regions are significantly longer than those expressed in collagen 
regions (Fig 3.4D). These data suggest that cilia size and number promote organization of 
the valve extracellular matrix into zonal boundaries characteristic of normal mitral valve 









Figure 3.4. Primary Cilia are Expressed in Areas Rich in Versican. (A) IHC of 
posterior leaflets show primary cilia marked with acetylated tubulin (green) co-stained 
with collagen (red) show few cilia within this region. (B) Immunohistochemical stains of 
primary cilia marked with acetylated tubulin (green) co-stained with versican (red) show 
increased expression of acetylated tubulin in areas of high versican expression. (C, D) 
Quantification of IHC stains at P0 showing a 70% decrease in cilia length and a 250% 
reduction in the number in collagen-rich regions. AVC=atrioventricular cushion.  Dotted 









To determine if primary cilia are necessary for mitral valve development we took a 
mouse genetics approach. As previously mentioned, Ift88 is an intraflagellar transport 
protein necessary for primary cilia formation. Conditional removal of Ift88 in the valves 
using the NfatC1cre driver was used to assess the role of primary cilia in the mitral valve. 
To confirm that cilia were lost using this system, IHC was performed on conditional 
wildtype, heterozygous and knockout animals. Staining showed partial loss of primary 
cilia in heterozygous animals and complete loss or very shortened cilia in knockout 
animals (Fig 3.5A). Histologically, the conditional knockout and heterozygous mice have 
enlarged anterior leaflets (Fig 3.5B). 3D reconstruction of H and E staining showed a 
trend towards significance of conditional heterozygous and a significant increase in 
anterior leaflet volume of the conditional knockout when compared to wildtype littermate 
controls (Fig 3.4C).  
Primary cilia play a role in sensing fluid movements in surrounding tissues. 
Motile cilia are used to propel molecules and objects across the surface of some tissues. 
In addition, many studies have shown that during valve development the biomechanical 
forces that are present play a major role in how the valves are formed. Therefore, one 
would hypothesize that primary cilia would be expressed on the surface of the valves. 
However, this is not what we observe. Very early during valve development (E9.5) we 
see some VEC primordia expressing primary cilia however the percentage is very small. 
Therefore, we hypothesized that the primary cilia expressed on the VICs are what is 
regulating valve development. To further address this question, we conditionally deleted 





Figure 3.5 Loss of Ift88 Impairs Ciliogenesis During Development and Leads to 
Enlarged Postnatal Mitral Valve. (A) IHC at postnatal day 0 show gene dosage effect 
for Ift88 on axoneme (green) formation in the mitral valves (white arrow heads). (B) H 
and E staining’s show that cHET and cKO have enlarged mitral leaflets. Student t-test of 
valve volumes obtained from 3D-reconstructions (C) show a trend towards significance 
in the cHET and a significant increase in valve volume in the cKO. AL=Anterior leaflet, 








Table 3.1 A list of Cre-lines and expected outcomes. VIC=valve interstitial cells, 




















As shown in Table 3.1, conditional deletion of Ift88 using the Nfatc1en-Cre would ablate 
cilia expression in only endocardial cells. We hypothesized that conditional loss of Ift88, 
with cre models that are expressed in VICs (periostin and NfatC1), will result in an 
enlarged valve phenotype. In addition, if ciliated VICs are regulating valve development 
then conditional loss of Ift88 in VECs, using the enhancer cre, will not have a phenotype.  
 Data show that conditional loss of primary cilia in VICs using the periostin cre 
driver results in an enlarged valve phenotype (Fig 3.6). This change trends towards 
significant but is not statistically significant(anterior leaflet p=0.31, posterior leaflet 
p=0.27). The anterior leaflet of these mice appear to be enlarged in specific regions and 
not uniformly large (Fig 3.6).  Further analysis looking at length and width measurements 
might be helpful in fully characterizing this phenotype.  
Surprisingly conditional loss of Ift88 with the enhancer cre driver resulted in 
significantly larger posterior leaflet and an anterior leaflet that was enlarged although not 
significantly so, when compared to wild type littermates (anterior leaflet p=0.03; 
posterior leaflet p=0.16) (Fig 3.6). There are two possibilities for why this phenotype 
may be occurring. First since we see very little to no primary cilia expression in the 
endocardial cells of the valve, loss of Ift88 may be playing a cilia independent roll in 
valve development. It has been shown that Ift88 can play a role in microtubule dynamics 
and cell migration independent of primary cilia (Borovina and Ciruna 2013, Boehlke, 
Janusch et al. 2015). There are, however, some endocardial cilia on the valves very early 
during development (E9.5-10.5). The other possible explanation is that loss of primary 
cilia on the endocardial cells during early valve development is enough to result in 
enlarged mitral valves.  
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Figure 3.6 Deletion of Ift88 using Periostin and Enhancer Cre models results in 
enlarged mitral valves. A. H and E and 3D reconstruction of Ift88 periostin and 
enhancer cre conditional knockout mice showed enlarged anterior leaflets when 
compared to control. B. Quantification shows a trend towards a significant increase in 
valve volume is seen in periostin cre posterior and anterior leaflets while a significant 
increase in volume is seen in the enhancer cre posterior leaflet.  
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 Since there was so much variation in the phenotypes that were observed we 
wanted to look at cre expression in these animals. To do this we used the Rosa26 green 
fluorescence protein (GFP) reporter mouse crossed with the NfatC1, periostin, and 
NfatC1-enhancer cre mice. This allows GFP expression in all cells that cre recombinase 
is active.  
Data show that the periostin and enhancer cre models are not as robust as originally 
thought (Fig 3.7).  GFP expression shows limited periostin cre activity in VICs as shown 
in figure 3.7. and the enhancer cre mouse also showed limited expression. NfatC1 
enhancer cre expression was seen on the ventricularius aspect of the valve with limited 
expression on the atrialus. Taken together, these data suggest that partial loss of primary 
cilia within the valve is sufficient to result in a phenotype. Therefore, to remain consistent 














Figure 3.7. Cre Recombinase Expression Patterns. IHC for GFP shows Cre activity 
under specific drivers. GFP expression in NfatC1 mice is nearly all valve cells. NfatC1 
enhancer expression is localized mainly to the ventricularus aspect and is absent in the 
majority of artrial endothelial cells. Periostin cre expression is found in VICs within the 
anterior and posterior leaflet but is not expressed by all VICs. AL= anterior leaflet, 
















One of the common themes among models with MVP is increased proliferation and since 
primary cilia regulate cell cycle we began by looking for changes in proliferation. We 
looked at proliferation of the Ift88 Nfatc1cre mice as a way of explaining the increase in 
valve volume. Data show no significant difference in proliferating cells in conditional 
heterozygous or knockout animals when compared to wild type littermates (Fig 3.8). To 
determine if the increase in valve size could be explained by increase infiltration or 
migration of cells, total cell numbers in each leaflet were also counted (Fig 3.8C). No 
difference was observed in total cell number of wildtype or conditional heterozygous and 
knockout animals. These data suggest that the increase in valve volume cannot be 
explained by increased proliferation or migration of cells in the conditional knockout and 
heterozygous leaflets.   
Another hallmark of myxomatous valve diseases is increased ECM so the increase in 
valve volume that was observed could be explained by increase in ECM.  To determine if 
there is more ECM in Ift88 conditional mice cell density was examined. Decreases in cell 
density, but no change in total cell number, would be explained by changes in ECM 
production. Decreased VIC density was observed in the anterior leaflet of conditional 
knockout animals (Fig 3.9). These data were then confirmed by whole transcriptome 








Figure 3.8 Loss of Primary Cilia have no Effect on Proliferation. (A) IHC for 
proliferating cells stained with ki67 (red) and myocardium stained with mf20 (green). (B) 
Quantification of the stains from A showing no significant difference in wildtype, 
conditional heterozygous and knockout leaflets. (C) Quantification of total cells in both 
anterior and posterior leaflets showed no significant difference in wildtype, conditional 
heterozygous and knockout leaflets.  AL= Anterior Leaflet, PL= Posterior Leaflet 
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Figure 3.9 Loss of Primary Cilia Results in Decreased Cell Density. (A) H and E 
showing areas of decreased cell density in the conditional knockout anterior leaflet. 
Boxes show representative area where cell counts were performed at the base, middle and 
tip of the leaflet. (B) Quantification of areas represented in A, at the base, middle and tip 
of the anterior leaflet. There is a significant decrease in the number of cells per area at the 







Figure 3.10:  Loss of Primary Cilia Results in Increased Expression of ECM 
Pathways. A. Perturbation vs. over-representation plot. The most significant change 
observed in RNAseq datasets was ECM/Receptor interactions (arrow and yellow circle) 
with a p-value= 1.12X10-8 B. mRNA transcript quantities of differentially expressed 
ECM genes.  Graphical representation of ECM genes that are significantly upregulated in 
the Ift88 conditional knockout mitral valves. Genes were selected based on p<.05. C. 
Pathway analyses of Differentially Expressed Genes. Pathway representation showing 
genes are increased in the Ift88 conditional knockout (red) or decreased (blue) and their 
intersection with receptor-mediated pathways. 
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Individual leaflets from wildtype and knockout animals were dissected and extracted 
RNA was analyzed. Of note markers of extracellular matrix were significantly increased 
in the conditional knockouts. These data confirmed that loss of primary cilia result in 
robust activation of fibrogenic and proteoglycan ECM gene programs that is consistent 
with early stages of myxomatous degeneration.  
 Further analysis was preformed to determine if the endothelial cell number was 
changed in these mice. Increases in valve volume should be associated with increases in 
endothelial cell number to compensate for the increased valve sizes.  However, when we 
counted total endothelial cells we found that there was no change in cell number between 
conditional knockouts and wild-type litter mates (Fig 3.11). This might be explained by 
changes in proliferation among the endothelial cells. To address this question, stains were 
done looking at proliferating endothelial cells. Again, no difference was observed 
between conditional knockout and wildtype valves in both anterior and posterior leaflets 
(Fig 3.11). These data suggest that loss of primary cilia results in increased valve volume 







Figure 3.11. Loss of Primary Cilia Results in Endothelial Cell Stretching. A. IHC 
showing stains for pcam (green) marking the endothelial cells, ki67 (red) marking the 
proliferating cells, and dapi (blue) staining the nuclei. B. Quantification shows no 
significant difference in total endothelial cell number or proliferation of endothelial cells 





Figure 3.12. Loss of Primary Cilia Leads to Myxomatous Mitral Valve Disease.  IHC 
(top and middle) and Movat's staining (bottom) of 4-6 month old Ift88 deficient mice 
show loss of normal versican and collagen boundaries and a myxomatous phenotype in 
conditional heterozygous and knockout animals (black arrows). Movats staining shows 
increased proteoglycans (blue), and collagens (yellow). AL, PL = Anterior and Posterior 








To determine if these developmental changes result in adult myxomatous mitral valve 
degeneration adult Ift88 conditional mice were analyzed. Histologically these mice 
develop myxomatous degeneration as shown by proteoglycan and collagen accumulation 
(Fig 3.12). H and E and Movat’s pentachrome stains show loss of normally stratified 
valves composed of distinct zones of elastin, collagen and proteoglycan in conditional 
heterozygous and knockout animals (Fig 3.12). Patients with myxomatous valve disease 
and MVP have disrupted matrix boundaries and increased production of collagens as seen 
in figure 3.13. The Ift88 conditional mice phenocopy the patients, having significantly 
increased collagen production and disruption of matrix boundaries as marked by 
increased blue staining in Herovici’s stain (Fig 3.13). Thus, loss of primary cilia causes 
developmental defects that are characterized by expansion of extracellular matrix and 
disrupted histological architecture that progress to an adult myxomatous valve pathology, 





Figure 3.13 Ift88 Conditional Mouse Models Phenocopy Matrix Disruption and 
Increased Collagen Deposition Found in Human Patient Valves. Herovici’s stains 
showing immature or newly synthesized collagen in blue and mature collagen in red. 
Both diseased human and mouse valves have blurring of mature and immature collagen 










Genetic association of Primary Cilia and MVP 
Based on these findings as well as evidence from the literature showing a 25% 
comorbidity of ADPKD and MVP, we hypothesized that primary cilia may play a broad 
role in mitral valve disease in humans. To test this hypothesis, we wanted to evaluate the 
link between the current MVP genes (DCHS1 and FLNA) and ciliogenesis. IHC staining 
for cilia in these mice showed significant decrease in cilia length. Dchs1 heterozygous 
mice had significant decrease in the number of ciliated cells at E17.5 (Fig 3.14). 3D 
reconstruction of primary cilia in these valves show significant loss of axonemes. 
Quantification showed a significant decrease in the number of ciliated cells (Fig 3.14). In 
addition, the Filamin A mouse model of MVP also had significant cilia loss. At postnatal 
day 0 of both Dchs1 knockout and filamin A conditional knockout showed significant 
decrease in average cilia length when compared to controls (Fig 3.15). These data suggest 











Figure 3.14 Dchs1 Heterozygous Mice have a Primary Cilia Defect. 3D reconstruction 
of cilia from E17.5 posterior leaflets show loss of axonemes (green) in Dchs1+/- mice. 
Red=Basal Bodies. Magnification of boxed area shown. >50% loss of cilia in VICs and 




Figure 3.15 Decreased cilia expression in knockouts associated with MVP. (A) IHC 
of P0 Dchs1 knockout and filamin-A conditional knockout mitral leaflets showing 
axonemes (acetylated tubulin-green) basal bodies (gamma tubulin-red).  (B, C) Grouped 
cilia length of Dchs1 knockout and filamin-A conditional knockout mice show a shift in 
grouped cilia length with the majority of cilia ~1.4µm in length while control P0 mice 
have the majority of cilia ~2.25 µm in length, which represents a 40% decrease in cilia 




We further evaluated broad involvement of the cilia pathway in MVP by 
analyzing GWAS data from 1,412 MVP cases and 2,439 control samples to test for 
global enrichment with significant association among a list of 278 different genes known 
to be involved in primary cilia biology, mainly as harboring rare mutations in a diverse 
panel of ciliopathies.  
We performed SNP test ratio method on several GWAS where phenotypes of 
cases and controls were permuted to generate 1000 simulated GWAS. Then, according to 
a pre-defined p-value threshold, the method consisted of counting the number of times 
the pathway tested included a higher ratio of significant to non-significant SNPs, 
compared to the 1000 simulated GWAS (Table 3.1). As recommended for this method, 
we used the KEGG pathways catalog in addition to our customized list of cilia genes. 
Given the limited number of highly associated SNPs in the current GWAS, we set 
significance at P<0.05 to allow more SNPs to contribute the analyses. Among nominally 
associated SNPs in the GWAS, we found that SNPs that map in the cilia genes list are 













Table 3.1: GWAS Phenotypes of Cases and Controls were Permuted to Generate 1000 
Simulated GWAS.  Among nominally associated SNPs in the GWAS (SNPs<0.05), we found 
that SNPs that map in the cilia genes list are more likely (trend P=0.034) to be enriched for 
associated SNPs with MVP. Of note, this analysis highlighted at the top 10 enriched pathways 
consistent cardiac enriched pathways including hypertrophic cardiomyopathy, dilated 









These data show for the first time that primary cilia are necessary for proper mitral valve  
development. Thorough these studies, we have shown that primary cilia are expressed 
both spatially and temporally on valvular interstitial cells but not endothelial cells as 
previously described. Similar to studies from the kidney, primary cilia in the heart 
increase in length with development, a phenomenon which is likely important in 
regulation of developmental processes occurring at the different stages. These primary 
cilia localize to areas of increased proteoglycan accumulation which has strong 
implications for a chemosensory roll. Further studies are needed to determine if primary 
cilia regulate ECM expression or if localization of cells within a specific ECM regulates 
the expression and length of a primary cilia.  
Primary cilia are necessary for proper valve development and when disrupted 
result in myxomatous valve disease. Our studies using the Ift88 conditional mouse model 
show loss of primary cilia prematurely results in increased postnatal valve volume. This 
increase in valve volume is not caused by increased proliferation, decreased apoptosis, 
increased infiltration of extra-cardiac cells or increased EMT. The increase in valve 
volume is caused by increased ECM expression as shown by decreased cell density and 
increased ECM expression. Since fibroblasts in the valve organize matrix, this increase in 
matrix could also be a loss of compaction issue. To determine this, further studies would 
be needed. Matrix compaction assays could be done by embedding VICs from Ift88 
control and conditional knockout mice in collagen gels and determining if the compaction 
of collagen is affected more in either genotype.  
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These changes shown during valve development change the structure and 
stratification of ECM expression which results in myxomatous adult valves. Conditional 
deletion of Ift88, and thereby primary cilia, result in myxomatous adult mitral valves. In 
this model we see blurring of matrix boundaries and increased collagen and versican. 
Additionally, conditional knockouts have increased collagen production indicating that 
matrix turnover is affected. More work could be done to determine if these mice do 
develop MVP. Echocardiography of aged mice to look for prolapse could be done.  
Additionally, Dhh has been shown in the literature to be important for endothelial 
boundary function and endothelial integrity. (Chapouly, Yao et al. 2016) Interestingly, in 
our Ift88 conditional knockout animals we saw no difference in total endothelial cell 
number. An increase in valve size but no increase in endothelial cell number suggest that 
the endothelial cells within the valve would have to stretch to compensate. This stretching 
may be leading to cytokine release which signals to circulating macrophages that the 
tissue was damaged. In other disease models and in human patients with myxomatous 
mitral valve disease, infiltration of immune cells is common.   
Human data further supports the hypothesis that primary cilia are important for 
proper valve function. GWAS analyses were performed on patients with MVP. Data 
show, increased association of ciliary genes with MVP patients. These studies suggest 
that primary cilia may play a broad role in the development of MVP. Previously 
identified MVP genes, Dchs1 and FlmnA, show decreases in primary cilia length as well. 
This novel finding provides further support for the role of primary cilia in valve disease.  
These studies show MVP is a congenitally based disease of the primary cilia that 
results in changes in ECM remodeling resulting in weakened valve leaflets. These leaflets 
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over time become myxomatous. The increase in valve size leads to strain on endothelial 
boundary formation ultimately leading to releases of cytokines and infiltration of 
macrophages as seen in Filamin A adult mice and human patients. This process occurs 
over many years in the patient’s life and therefore MVP patients are often asymptomatic 




















CHAPTER 4: MUTATIONS IN DZIP1 CAUSE  






















Currently little is known about the etiology of MVP. Familial studies have provided 
evidence for a genetic association but until recently a causal gene has not been identified. 
Informative studies from our lab has shown an association between primary cilia and 
valve disease. Published literature shows a 25% comorbidity between MVP and an 
established ciliopathy ADPKD. In addition, our data from Ift88 cilia knockout mice show 
that primary cilia are important for valve development and cause myxomatous valve 
disease when disrupted. These data suggest that primary cilia are important for proper 
valve development and when disrupted play a role in the development of MVP.  
 In order to further evaluate the role of primary cilia in MVP, we examined our 
patient data to determine if cilia genes were associated with the linked region. Analysis 
was done on a multi-generational family with inherited autosomal dominion MVP 
previously linked to chromosome 13 (Fig 4.1). Out of 43 individuals enrolled in the 
original study, nine patients met the full clinical diagnostic criteria for MVP, with two 
individuals having moderate to severe MR and one with ruptured chordae that required 
surgical intervention.  Additionally, six were coded as minimal MVP, and two had 
prodromal pre-clinical forms, which have recently been reported to progress and have a 
familial association. None of the individuals in the pedigree exhibited extracardiac 
manifestations, and all MVP-affected individuals were deemed as “non-syndromic”. 
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Figure 4.1 Identification of DZIP1 as an MVP gene. (A) Multigenerational family with 
inherited, autosomal-dominant, non-syndromic MVP. ?= unknown phenotype.  (B) 
Human transcript and marker maps of the linkage interval on chromosome 13.  Candidate 
region is within 13q31.3-32.1, and all RefSeq genes and their orientations are shown 
within the 8.2-Mb interval.  DZIP1, the only cilia gene within the locus is highlighted in 
pink. (C)  Western analyses and statistical analyses (t-test) for DZIP1 showing that each 
of the 3-affecteds analyzed had a significant reduction (p=.016, p=.011) in DZIP1 
protein expression. Sanger sequencing identified a single missense mutation within exon 






Figure 4.2 Echocardiography of Proband from Chromosome 13 family.  (A) 
Parasternal long-axis view of proband from US family showing prolapse (blue arrows) 
above the annulus during ventricular systole (dotted line). (B) Significant MR is observed 















The proband of this family displayed significant bileaflet prolapse coincident with mitral 
regurgitation (Fig 4.2). The linkage peak spanned 8.2 Mb and included 14 genes (Fig 
4.1).  In order to define the putative MVP gene(s) in this family, we used a candidate-
based approach. DZIP1 was the only gene within the linkage region that had previously 
been shown in other model systems to regulate ciliogenesis and/or cilia signaling. 
What is Dzip1? 
DZIP or DAZ-interacting protein was originally identified in zebrafish where it 
was shown to interact with DAZ (Moore, Jaruzelska et al. 2004). DAZ and DAZ-like 
proteins (DAZL) are expressed in the developing testies and ovary where they function in 
early germ cell development. Their expression is gone by early somatic cell generation 
but DZIP expression is maintained and expressed by neuronal cells. Dzip1 is a 
centrosomal protein that is important for ciliogenesis, vesicle transport to the primary 
cilium, and downstream Hh signaling. Loss of Dzip1 results in loss of primary cilia. In 
zebrafish, the gene igu encodes for Dzip1 which is shown to localizes to lysosomes and 
endosomes(Sekimizu, Nishioka et al. 2004). For this reason, Dzip1 has been implicated 
shuttling proteins between the nucleus and cytoplasm.  
Dzip1 is an important regulator of Hh signaling. In igu mutants, Hh signaling is 
impaired with decreased Gli activator formation and increased Gli repressor suggesting 
that Igu/Dzip1 function is required for full activation of Gli proteins in response to Hh 
signals(Sekimizu, Nishioka et al. 2004). In addition, Dzip1 is the bridge between IFT88 
and Gli3. It has been shown to bind Gli3, but not Gli1 or Gli2, preventing Gli3 protein 
from entering the nucleus. Loss of Dzip1 in mice leads to accumulation of Gli3 in the 
nucleus(Wang, Low et al. 2013).  
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Vesicle transport also plays a very important role in the formation of the primary 
cilia. In mouse embryonic fibroblasts (MEFs), Dzip1 localizes to the basal body and 
shuttles IFT88 to the distal appendages of the mother centrioles during cilia 
formation(Wang, Low et al. 2013). Loss of Dzip1 results in loss of primary cilia. Dzip1 
localizes to the centrosome during cell division and promotes the release of Rab8GDP. 
Rab8 is the core mediator of vesicle trafficking to the cilium and loss of Rab8 
localization or inhibition of the formation of Rab8GDP leads to improper cilia 
formation(Zhang, Zhang et al. 2015). In addition, the BBSome proteins are essential for 
regulating vesicle transport and localization of proteins to the primary cilia for assembly. 
First discovered in patients with Bardet-Biedl syndrome, the BBSome consists of 
multiple proteins which assemble to bind and target membrane vesicles by reading 
signals on vesicles destined for the ciliary membrane(Jin, White et al. 2010). Dzip1 plays 
a role in this process through its binding of PCM1 which mediates the recruitment of the 
BBSome to the centrosome(Zhang, Wang et al. 2017).  
Results 
We began our experiments by examining if Dzip1 is expressed in the developing 
mitral valve. RNA in situ and IHC experiments revealed robust expression of Dzip1 in 
the developing anterior and posterior mitral leaflets, with protein expression being 





Figure 4.3 Expression of Murine Dzip1. (A) Section in situ of Dzip1 at E14.5 showing 
robust mRNA in the anterior and posterior mitral leaflets (AL, PL, respectively). (B) IHC 
for Dzip1 (red) and axonemes (green) or basal bodies (green) showing expression of 











Western analyses of lymphoblasts from affected and unaffected family members 
revealed significant down-regulation of DZIP1 protein expression (Fig 4.1). Sanger 
sequencing of DZIP1 revealed a proline-to-serine change in two known DZIP1 isoforms 
(p.S70R, p.S24R). Whole exome sequencing (WES) confirmed that no other coding 
changes were present within the linkage interval. Sanger sequencing of all members of 
the family confirmed segregation of the DZIP1 variant. A second, three-generation, 
family of European descent was identified with autosomal dominant MVP, and WES 
followed by Sanger sequencing identified the same P.S70R, p.S24R change in DZIP1 
affected individuals (Fig 4.4). Minor allele frequency analyses in ExAC/gnomAD 
revealed that this variant is exceedingly rare, and was never observed in 122,000 exomes, 
and only once in 15,500 genomes. To test whether Dzip1 plays a significant role in 
ciliogenesis and MVP, conditional ablation of Dzip1 (with NfatC1cre) was performed in 










Figure 4.4 Identification of additional MVP family with a DZIP1 mutation. (A) 
Pedigree of family showing inherited, autosomal dominant MVP. += DZIP1 mutation 
carrier with the same mutation (p.S24R, p.S70R) as the original family. Grey box is an 
individual that lacks a DZIP1 mutation but has MVP.  This individual has a different 
disease presentation with more symmetrical prolapse and altered anterior displacement of 
the coaptation point, suggesting a discordant phenotype unrelated to DZIP1 variants. (B, 





Figure 4.5 Conditional deletion of Dzip1 results in increased postnatal valve 
size. (A) IHC, H & E, and 3D reconstructions show loss of primary cilia (acetylated 
tubulin-green) and increased valve size in conditional heterozygous and knockout mice at 
P0. Basal bodies (gamma tubulin-red) and nuclei (Hoechst-blue). (B) Quantification of 
3D reconstructions in A (*=p<.005). (C) Quantification of grouped cilia length in WT, 
conditional heterozygous (cHET) and conditional knockout (cKO) anterior leaflets 
showing decreased cilia length in cHET and cKO.  
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IHC showed loss of primary cilia in conditional knockout animals and partial loss 
in conditional heterozygous animals (Fig 4.5). The cilia that were present in these leaflets 
were significantly shorter than their wild type littermate controls. Histologically, 
conditional heterozygous and knockout animals had enlarged valve size as shown from H 
and E staining as well as 3D reconstruction (Fig 4.5). Both anterior and posterior leaflet 
volume of both heterozygous and knockout animals were significantly larger when 
compared to wild type littermates. 
Previous research has shown Dzip1 to sequester Gli3 in the cytoplasm promoting 
its cleavage and preventing its localization in the nucleus (Wang, Low et al. 2013). 
Therefore, we wanted to asses Gli3 processing in the Dzip1 conditional mice. Protein was 
taken from single anterior leaflets of Dzip1 conditional heterozygous, knockout and 
control animals. Western blots were run and probed with Gli3 antibody. Data show no 
change in Gli3 cleavage between conditional heterozygous, knockout and control animals 
(Fig 4.6).  
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Figure 4.6 Conditional Loss of Dzip1 Does Not Change Gli3 Processing. Western blot 
of mouse AV cushion cell lysate probed for Gli3 shows no change in levels of Gli3R/Fl. 
B. Quantification of Gli3 western blot showing no significant difference in levels of 










To determine if loss of Dzip1 and primary cilia play a role in the development of 
mitral valve prolapse, adult mice were assessed. Additional analyses of adult Dzip1 
conditional knockout mice (using either NfatC1Cre or Tie2Cre) revealed a myxomatous 
phenotype with increased proteoglycans and collagen and loss of the normal ECM zonal 
boundaries, observed in control mitral leaflets (Fig 4.7).  
Functional echocardiographic assessment revealed that these structurally altered 
mitral valves exhibited prolapse and leaflet elongation in conditional heterozygotes (2 out 
of 4) and knockout animals (4 out of 5) (Fig 4.7).  MVP was never observed in control 
animals and there were no statistically significant alterations in ventricular contractile 
function between the conditional Dzip1 heterozygote, knockout and control animals (Fig 
4.8).  Interestingly, we noted a gene dosage affect in which loss of one allele of Dzip1 
was sufficient to perturb ciliogenesis during development and engender a mitral valve 
phenotype in the adult. These data support our finding of a rare, damaging DZIP1 
missense mutation in two families with MVP, which support the proposed hypothesis that 










Figure 4.7  Loss of Dzip1 Results in Myxomatous Adult Mitral Valves. IHC 
and Movat’s stains in adult Dzip1 conditional wildtype heterozygous and knockout 
animals show significant enlargement in valve size and blurring of matrix boundaries. 
Dzip1 conditional heterozygous and knockout animals have increased collagen (top) and 




Figure 4.8 Dzip1 Deletion Results in MVP. Parasternal long-axis views of Dzip1 
deficient mitral leaflets shows leaflet elongation and bileaflet prolapse during ventricular 









These data are the first to show cilia are important for the proper development of the 
mitral valve. Disruption of cilia through deletion of Dzip1 results in enlarged postnatal 
mitral leaflet that develop into myxomatous adult valves. Loss of Dzip1 results in MVP 
in adult mice as shown by echocardiography and this phenotype is what is seen in 
patients with Dzip1 mutations. Further studies need to be done to identify a mechanism 
by which Dzip1 mutations result in decreased cilia length. Preliminary data in the lab 
suggest that this mutation may disrupt binding to important molecules involved in 
ciliogenesis. Generation of the point mutation mouse has provided insight into the 
biology of the patients with Dzip1 mutations. Preliminary data from these Dzip1 point 
mutation knockin mice show enlarged postnatal leaflets as well as myxomatous adult 
leaflets.  
 In order to determine the mechanism by which Dzip1 deletion results in MVP 
further experiments are needed. Loss of Dzip1 in mouse models results in myxomatous 
valve phenotype similar to the Ift88 conditional mice. Increases in ECM is seen in both 
models. To further evaluate these changes RNA seq could be done at a time point prior to 
valve enlargement, such as E13, to compare changes between Ift88 and Dzip1 conditional 
mice. Further studies looking at hedgehog signaling may also prove valuable. Since 
Dzip1 has been previously implicated in sequestering Gli3 in the cytoplasm but we see no 
change in Gli3 processing IHC looking at Gli3 localization in conditional knockout mice 





CHAPTER 5: OVERALL DISCUSSION 
Valve disease is one of the most common cardiac diseases affecting between 0.5-
2% of individuals. MVP and BAV are two of the most common valve diseases and  
currently the only treatment option is surgical replacement or repair. The etiology of 
these diseases are poorly understood however evidence has shown a developmental 
origin. Better understanding of these developmental processes and signaling pathways 
has provided insight into the mechanism by which primary cilia regulate ECM 
production. Future work is still needed to identify which signaling pathway is responsible 
for this regulation although some evidence suggests non-canonical hedgehog signaling is 
playing a role.  
Currently the only treatment option for  both MVP and BAV is invasive surgery 
to either repair or replace the damaged valve. For patients with BAV and aortic stenosis, 
the gold standard of treatment is surgical aortic valve replacement (SAVR) which has 
proven to be both symptomatic and provide survival benefits (Al Kindi, Salhab et al. 
2014). Over the past decade these procedures have improved greatly and inventions such 
as the MitraClip, a trans catheter mitral valve repair device designed to reduce MR,  has 
helped patients live longer healthier lives (Velazquez, Samad et al. 2015). However, there 
is still room for improvements. Secondary complications caused by valve disease cause 
damage to the heart in other ways resulting in long term cardiovascular disease and 
current treatment options are often invasive, risky and not always suitable for the elderly 
population most often effected by these diseases. Devices such as the MitraClip help 
improve the 30-day mortality of 7.7% of MitraClip patients compared to what is 
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predicted had mitral valve surgery been attempted. However, these devices are not 
perfect. The Endovascular Valve Edge-to-Edge Repair Study (EVEREST II) study 
showed mitral valve surgery was more effective in reducing MR than the MitraClip 
(George, Varghese et al. 2011, Velazquez, Samad et al. 2015). For these reasons a better 
understanding of the developmental origins and molecular mechanisms for these diseases 
will allow clinicians to move forward with less invasive more effective treatment options.  
Structural changes that occur in the valves of patients with MVP and BAV 
include myxomatous degeneration. A myxomatous valve has increased accumulation of 
proteoglycans, fragmented collagens, and hyperplasia. Over time, these changes in the 
histoarchitecture of the valve result in mechanically weakened structure which become 
elongated and, in the case of MVP, are susceptible to prolapse. Little is known about how 
the valves become myxomatous although evidence points to a genetic origin.  
Our studies suggest that primary cilia play a major role in this process. Through 
spatial and temporal regulation of valve differentiation and matrix deposition, the primary 
cilia act as molecular clocks. In this way the primary cilia relay information to the cell 
telling it what stage in development the tissue is undergoing and allowing the cells to 
differentiate producing the correct ratio of ECM at each stage of development. Loss of 
this signal results in improper valve differentiation and matrix deposition. Structural 
changes during development then progress to adult valve disease because the tissue is 
compromised at an early age. Over the course of the patients life, enlarged postnatal 
leaflets cause endothelial boarders to stretch and weaken which potentially allows for 
cytokine release and infiltration of extracardiac cells. Previous models of myomatous 
valve disease show infiltration of hematopoetic derived CD45 positive cells. This 
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infiltration leads to increased MMP secretion and further matrix degradation. At this 
stage in a patient’s life they may become symptomatic while early in life when the 
disease is still occurring they would be considered non-symptomatic. For these reasons, 
understanding the processes involved in mitral and aortic valve development are essential 
in determining a molecular mechanism for valve disease.  
In our studies we noticed the development of BAV in our Ift88 conditional 
knockout mice but not in our Dzip1 conditional knockout mice. If both genes affect 
primary cilia,  how can this be the case? The severity of cilia loss may be an explanation. 
Conditional deletion of Ift88 to remove primary cilia is the most severe level of cilia loss 
while deletion of Dzip1 deletion is a less severe. Ift88 conditional knockout mice develop 
both MVP and BAV while conditional heterozygous only develop MVP. In the Dzip1 
conditional knockout mice we observed MVP but not BAV. The Ift88 conditional 
knockout mice have almost complete cilia loss with a few very short cilia while the 
Dzip1 conditional knockout mice have shorter cilia.  
An additional explanation could be differences in tissue expression of the 
molecules involved in Dzip1 signaling.	 The “ciliome” constitutes ~2-3% of all 
mammalian genes and it’s likely that components of the ciliome are expressed in unique 
spatial, temporal, and tissue-specific manners, such that the mitral and aortic valves differ 
in presence/expression of subsets of cilia genes.	  It is possible that Dzip1 signaling is 
more important for mitral valve development than aortic valve development. To test this 
stains for various pathway members could be done in both mitral and aortic valves to see 
if there was variation in expression. IHC showing differences for any of the Gli 
transcription factors, members of the non-canonical HH pathway such as Rac and Rho, or 
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PDGFRα signaling pathway such as AKT, or PI3K could explain differences in 
phenotypes.  
More work is needed to determine a signaling mechanism for these changes. In 
both aortic and mitral valves, loss of primary cilia with conditional deletion of Ift88 
resulted in increased ECM production and decreased cell density. Determining how loss 
of primary cilia results in increased matrix proved to be complicated but we can speculate 
about what pathways may be involved. Since loss of Dhh resulted in a valve phenotype 
similar to that seen with deletion of Ift88 it is possible that the HH signaling pathway is 
involved. No change was observed in processing of Gli3 which could mean that Gli2 is 
playing a role or that Dhh is signaling in a non-canonical way. To further evaluate these 
pathways multiple experiments could be done. Western blots using tissue from Dzip1 and 
Ift88 conditional knockout and wild type tissue could be probed for PERK, pAKT, PI3K 
or Gli transcription factors. To determine if non-canonical HH signaling is occurring a 
Rac/Rho activity assay can be done. In this assay, Rac/Rho in its active form, bound to 
GTP, is pulled down using a specific antibody. The protein is then eluted off the beads 
and can be run in on a western blot to look at relative abundance.  
From the data collected we propose the following working model. Inhibition of 
ciliogenesis, reception of signal by the cilia, or deletion of ligand needed for cilia 
signaling results in improper valve development ultimately leading to valve disease. 
Disruption of cilia structure through deletion of Ift88 results in myxomatous mitral and 
aortic valves with a high penetrance of BAV. These mice develop enlarged mitral valves 
with increased expression of versican and collagen. A similar phenotype is observed in 
the Dzip1 conditional knockouts. Conditional loss of Dzip1results in enlarged 
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myxomatous mitral valves that ultimately results in MVP. Disruption of the HH ligand 
Dhh also causes enlarged postnatal valves although the mechanism by which this is 
occurring is still under investigation.  
In the future this work has the potential to influence therapies for these diseases. 
One common thread between multiple models of valve disease is the disruption of the 
ECM boundaries. If a therapy could target this disruption we could potentially stop 
further degradation of the matrix and maintain a functional valve leaflet. Therapies using 
Nano particles are appealing for this function. Using antibody targeted against 
fragmentation of collagen or elastin tethered to nanoparticles which are filled with drugs 
we could possibly target the damaged tissue before further issues could arise. One 
potential drug option would be something that repairs fragmented elastin or collagen. 
Another potential option could be a crisper molecule that could repair the mutation that is 
seen in the patients with the DZIP1 mutations.   
More work is still needed to further elucidate the molecular mechanisms involved 
in valve disease, however, substantial progress has been made. The concept of valve 
disease as a ciliopathy is a novel idea and opens up the potential for further research 
which is likely to help undercover the ethology of these diseases.   Here we present 
genetic, cellular and molecular data to broadly support primary cilia defects as a cause of 







CHAPTER 6: MATERIALS AND METHODS 
Mouse Studies 
All mouse experiments were performed under protocols previously approved by the 
Institutional Animal Care and Use Committee (IACUC) at the Medical University of 
South Carolina.  Prior to cardiac resection, mice were euthanized in accordance with the 
Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 
1996.) Comparisons between sexes were evaluated and no significant differences were 
observed. As such, data is comprised of pooled sexes for all experiments. Mating 
strategies were as follows. Female mice heterozygous for the conditional “floxed” allele 
of each respective gene (Ift88, Dzip1, and Dhh) were bred with male transgenic mice 
who were heterozygous for the conditional “floxed” allele as well as expressing Cre 
under the control of the respective promoters (NfatC1, NfatC1- enhancer, Periostin, or 
Tie2). Mice resulting from these mating would be Cre negative or positive and had the 
potential to be wildtype, heterozygous or homozygous for the floxed allele. Filamin A 
conditional mice were bred similarly but male mice were conditional knockouts as 
FilaminA is X chromosome specific. Dchs1 global mice were generated using a 
heterozygous female with a heterozygous male. All mice were outbred. 
 
IFT88 conditional mice 
Ift88 conditional mice and genotyping were previously described(Haycraft, Zhang et al. 
2007). Histology was performed on embryonic and adult wild-type (NfatC1Cre-;Ift88f/f) 
conditional heterozygous (NfatC1Cre-;Ift88f/+) and conditional knockout (NfatC1Cre+;Ift88f/f) 
hearts on mixed background.  
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Dzip1 conditional mice 
Conditional knockout mice were generated by a targeted homologous recombination 
approach using a Dzip1 targeting construct (PG00125_Z_2_E04) purchased from the 
KOMP mouse repository. The conditional knockout would delete exons 8 and 9 (Dzip1-
202 transcript) and cause a reading frame shift and premature translational termination. 
The conditional mutant allele was genotyped using forward primer: 5’-
GCCAAAGTGGTTTGCCTGACA -3’ and reverse primer: 5’-
GCAGGTTAAACACTCATATAGC-3’ (210bp for wt and 290bp for mutant). Histology 
was performed on embryonic and adult wild-type (NfatC1Cre-;Dzip1+/+) conditional 
heterozygous (NfatC1Cre+-:Dzip1f/+) and conditional knockout (NfatC1Cre+;Dzip1f/f) hearts 
on mixed background. Additional wild-type (Tie2Cre+;Dzip1+/+) and conditional knockout 
(Tie2Cre+;Dzip1f/f) adult hearts were examined as well.  Data collected from the NfatC1 
and Tie2 Cre lines were comparable. 
 
Histology, Immunohistochimistry/Immunofluorescence 
Embryonic and adult tissue were processed for hematoxylin and eosin (H and E) staining, 
Herovici’s collagen stain and, immunohistochemistry/immunofluorescence (IHC) as 
previously described. IHC of cilia stains to look at expression and measure cilia length 
were done on 15 µm thick sections to insure measurement of full cilia length. Histology 
and IHC were preformed using 5µm thick sections from E11,13,15,17, P0, and Adult (4-
8month) aortic valves. H and E stains were performed as previously described. Herovci 
stains were preformed using American MasterTech Herovici’s Collagen Stain Kit 
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Procedure (cat#KTHER). For immunohistochemistry (IHC): Antigen retrieval was 
performed for 1 minute using antigen unmasking solution (Vector Laboratories, 
Burlingame, CA, USA, Cat#H-3300) by pressure cooker (Cuisinart, Stamford, CT, 
USA). The following are the antibodies and their dilutions; Acetylated Tubulin (Sigma, 
Cat#T6793, 1:500), Gamma Tubulin (Abcam, Cambridge, MA, USA, Cat#ab11317, 
1:1000), Versican (gift from Stan Hoffman, Medical University of South Carolina, 1: 
250), Collagen (gift from Stan Hoffman, Medical University of South Carolina, 1: 250), 
MF20 (DSHB, Iowa City, IA, USA, Concentrate, I:50), Ki67 (Abcam, Cat#ab16667, 
1:250), Phospho-histone H3 (EMD Milipore, Darmstadt Germany, Cat#06-570, 1:250), 
Smoothened (LSBio, Seattle WA, Cat#LS-A2666, 1:250), Gli3 (Origene, Rockville MD, 
Cat#TA337186, 1:250). Primary antibody was detected using fluorescent secondary 
antibody, Goat anti-Mouse IgG Alexa fluro 488 (Cat#A-11029, 1:100), Goat anti-Rabbit 
Alexa fluor 488 (Cat#A-11034, 1:100) anti-Mouse Alexa fluor 568 (Cat#A-11004, 
1:100), anti-Rabbit Alexa fluor 568 (Cat#A-11036, 1:100) Cy5 goat anti-Mouse (Cat#A-
10524, 1:100) and Cy5 goat anti-Rabbit (Cat#A-10523, 1:100)  (Life Technologies, 
Rockville, MD, US). Nuclei were counterstained with Hoechst (Life Technologies, Cat 
#H3569, 1:10,000) for 10 minutes and slides were coverslipped with SlowFade mounting 
medium (Life Technologies, Cat#S36937). Fluorescence imaging was preformed using 
Zeiss Axioimager M2 and Leica TCS SP5 AOBS Confocal Microscope System.  
 
Confocal Microscopy 
Images were acquired using the Leica TCS SP5 AOBS Confocal Microscope System ( 
Leica Microsystems, Inc., 410 Eagleview Boulevard, Suite 107, Exton, PA 19341). Z-
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stacks were set by finding the highest and lowest depth with visible fluorescence and 
using the system optimized setting to determine steps. Z-stacks were then compiled to 
form maximum projection images.  
 
3D reconstruction 
3D reconstructions of H and E images were preformed to generate volumetric 
measurements of postnatal day 0 right, left, and non-coronary leaflets, similarly to 
previous reports. Briefly, 5µm sections throughout the width of the aortic valve were H 
and E stained and imaged using the Olympus BX40 bright field microscope. Images were 
then aligned using ImageJ FIJI and imported into Imaris 8.0. Manual reconstruction was 
performed by tracing each individual cusp on every section and combining all traces to 
create a 3D structure.  Additionally, 3D reconstructions of immunohistochemistry were 
performed by importing Z-stack images of 15µm sections into Imaris and creating 
surface renderings based on intensity of the stains.  
 
Quantifications 
Cilia length measurements were performed using Z-stack images of right coronary cusps 
(Chapter 2) or posterior leaflets (Chapter 3 and 4) stained with acetylated alpha tubulin, 
gamma tubulin and counterstained with Hoechst. Z-stack images were then imported into 
Imaris software and measurements were taken from the base to the tip of the axoneme. 
All cilia in the field of view were measured, n=3 per developmental time point or 
genotype. Measurements were then ranked and grouped; zero microns represents absence 
of cilia. Quantification of cilia length in versican and collagen regions was performed on 
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left coronary leaflets in the same way, n=3. Average cilia length was then calculated and 
Student’s t-test was done (p<0.001).  
Cell density quantifications were measured by counting all nuclei in a specified area, 
25.4mm2 for post-natal measurement and 22 mm2 for adult measurements. Postnatal 
measurements were taken at the base and tip of the right coronary leaflets, n=3. Adult 
measurements were taken at the tip of right coronary leaflets, n=3. Measurements were 
compared to wild-type data to generate fold change and statistical significance was 
calculated using a Student’s t-test (p<0.001).  
Quantification of Collagen was preformed using Herovici stained right coronary leaflets. 
Surface area of red staining was measured in Image J and percentages were calculated 
based on total leaflet surface area. n=3, with three areas per animal measured.  
 
RNA Seq analysis 
Mitral leaflets were dissected from P0 NfatC1Cre(+); Ift88f/f and P0 NfatC1Cre(+), Ift88+/+.  
Total RNA was isolated using MicroRNeasy (Qiagen). Purity and quantification was 
determined by Bioanalyzer.  The library preparation was made using the SMART-Seq® 
v4 RNA-seq kit(Clontech Laboratories, Mountain View, CA) following the 
manufacturer's instructions.  
The analysis was carried out on an OnRamp Bioinformatics Genomics Research Platform 
(OnRamp Bioinformatics, San Diego, CA).  “OnRamp’s advanced Genomics Analysis 
Engine utilized an automated RNAseq workflow to process the data, including (1) data 
validation and quality control, (2) read alignment to the mouse genome (mm10) using 
STAR RNA-seq aligner, (3) generation of gene-level count data with HTSeq, and (4) 
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differential expression analysis with DEseq2, which enabled the inference of differential 
signals with robust statistical power(Dobin, Davis et al. 2013, Love, Huber et al. 2014, 
Davis-Turak, Courtney et al. 2017). Transcript count data from DESeq2 analysis of the 
samples were sorted according to their adjusted p-value or q-value, which is the smallest 
false discovery rate (FDR) at which a transcript is called significant. FDR is the expected 
fraction of false positive tests among significant tests and was calculated using the 
Benjamini-Hochberg multiple testing adjustment procedure(Benjamini and Hochberg 
1995). The DE list was them submitted to the iPathway Guide tool from Advaita® 
Bioinformatics, this tool uses a systems biology approach in order to identify pathways 
that are significantly impacted in any condition - from high-throughput gene expression 
data. The impact analysis incorporates the classical probabilistic component of the 
magnitude of the expression changes of each gene, the position of the differentially 
expressed genes on the given pathways, the topology of the pathway that describes how 
these genes interact, and the type of signaling interactions between them(Draghici, Khatri 
et al. 2007). 
 
Echocardiography 
Mice were anesthetized with 3–5% isoflurane vapor in an anesthesia chamber and then 
placed on a biofeedback warming station with nose cone anesthesia of 1.5–2.5% 
isoflurane, which was regulated to maintain a heart rate between 500 to 600 beats/min, 
while providing anesthesia (abolition of the toe pinch reflex). The hair over the chest was 
removed using a commercially available depilatory cream.  Ultrasound gel was placed on 
the chest, and echocardiography measurements were performed using a 40-MHz probe 
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with a spatial resolution of 30 µm (Vevo2100; Visualsonics). Two-dimensional and M-
mode echo images were obtained in the parasternal short- and long-axis views. LV 
volumes and ejection fractions were computed from the parasternal long-axis recordings 
and LV mass was computed from the short axis measurements (Mani, Balasubramanian 
et al. 2009, Kholmukhamedov, Logdon et al. 2014, Zavadzkas, Stroud et al. 2014).  For 
terminal studies, heart harvest was performed following this procedure. The entire 
echocardiography procedure took ∼20-30 min per mouse. 
 
Human Studies 
Fetal hearts (12 and 20 weeks) were obtained from elective terminations that were 
lawfully performed at Brighman and Women’s Hospital, Boston, MA under IRB 
approval (2010P001333). Samples were stored in RNA later and maintained at the 
Harvard BioBank.  Tissues were washed and refixed in formalin followed by tissue 
processing, embedding and sectioning as we have previously described (Durst, Sauls et 
al. 2015).  MVP was diagnosed in two-dimensional long-axis echocardiographic views 
by >2mm leaflet displacement superior to the annulus hinge points (Levine, 
Stathogiannis et al. 1988, Levine, Handschumacher et al. 1989). Prodromal morphology 
was noted based on leaflet coaptation abnormally displaced >40% anterior relative to the 
mitral annulus, and minimal superior displacement was based on <2mm displacement 
(Nesta, Leyne et al. 2005, Delling, Gona et al. 2014).  These morphologies associate with 
progressive prolapse (Delling, Rong et al. 2016)and link to the haplotype of affecteds 




Complete details on the family in Figure 3A and the original linkage analysis can be 
found in (Nesta, Leyne et al. 2005).  Epstein Barr Virus (EBV) transformed lymphoblast 
cell lines were created on all members of the family available for study.  Protein was 
isolated from cultures for the individuals marked with a “*” in Figure 3A and Western 
analysis performed using a DZIP1 rabbit monoclonal antibody (epitomics)   Sanger 
sequencing using primers for each exon of DZIP1 was performed for all members of the 
pedigree.  Exome sequencing was performed on four individuals carrying the linked 




Family 2 Genetics: 
PCR reactions & High-Resolution Melting (HRM) Analysis 
PCR for HRM assay were performed in “LightCycler® 480 Multiwell Plate 96, white” 
reaction plates. 12.5 ng of genomic DNA and 0.25µM final concentration of each primer 
were used per reaction (10µL final volume). 
 
Reagent 
Volume per well 
(µL) 
 
Water, PCR Grade 2.5 
 
Primer Forward (10µM) 0.25 
 
Primer Reverse (10µM) 0.25 
 
LightCycler® 480 Probes Master, 2x 
concentrated 5 
 
LightCycler® 480 ResoLight Dye, 20x 
concentrated 0.75 
 
DNA sample (10ng/µL) or Negative 
control (Water) 1.25 
The PCR and HRM assays were performed on the “LightCycler® 480 Instrument” 
(Roche). Run and analysis are performed with the “LightCycler® 480 Software Version 
1.5” and the “LightCycler® 480 Gene Scanning module” (Roche). 
For “ResoLight Dye” detection, the filter “SYBR Green I / HRM Dye (465-510 nm)” 
was selected (Integration Time Mode: Dynamic). 
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Initial activation step was set at 95°C for 10min (Ramp rate 4.4°C/sec), followed by a 55-
cycle program [denaturation, 95°C for 15sec (Ramp rate 4.4°C/sec); annealing, 
touchdown 68°C to 55°C (with 1°C step size and 1 cycle step delay) for 15sec (Ramp 
rate 2.2°C/sec); and elongation, 72°C for 20sec (Ramp rate 4.4°C/sec); acquisition mode, 
“Single”]. The subsequent melting program included three steps: denaturation at 95°C for 
1 sec (Ramp rate 4.4°C/sec), renaturation at 40°C for 30sec (Ramp rate 2.2°C/sec), and 
then melting from 65°C to 97°C (Ramp rate 2.2°C/sec) with 25 acquisitions per °C 
(Ramp rate 0.02°C/sec); acquisition mode, “Continuous”) and a final cooling step was set 
at 50°C for 30sec (Ramp rate 2.2°C/sec). Finally, after the run analysis, real-time PCR 
products were directly sequenced in order to obtain the clusters genotype (few samples 
from each curve cluster). Sanger sequencing was performed on the same PCR amplicons 
and primers, using standard conditions. 
Genome wide association (GWAS) study on Cilia 
Using our previous GWAS on MVP (Dina, Bouatia-Naji et al. 2015), we tested for a 
global enrichment for significant association among a large list including 278 different 
genes reported as involved in cilia biology, mainly as harboring rare mutations in a 
diverse panel of ciliopathies. We used the SNP test ratio method as described in 
(O'Dushlaine, Kenny et al. 2009). In this analysis we first performed several GWAS 
where phenotypes of cases and controls were permuted to generate 1000 simulated 
GWAS. Then, according to a pre-defined p-value threshold, the method consists in 
counting the number of times the pathway tested included a higher ratio of significant to 
non significant SNPs, compared to the 1000 simulated GWAS. As recommended for this 
method, we used the KEGG pathways catalog, in addition to our customized list of cilia 
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genes. Given the limited number of highly associated SNPs in the current GWAS that 
includes ∼1500 cases and 2500 controls, we set significance at P<0.05 to allow more 
SNPs to contribute the analyses.  Among nominally associated SNPs in the GWAS 
(SNPs<0.05), we found that SNPs that map in the cilia genes list are more likely to be 
associated with MVP (P=0.03).  
 
Statistics 
Statistical significance was determined using a student’s t-test (two tailed, type 2) with 
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